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The non-medical use of prescription drugs has become a global 
health concern. Non-medical usage is defined as the taking of 
prescription drugs, whether obtained by prescription or otherwise, 
except in the manner or for the reasons or time period prescribed, or 
by a person for whom the drug was not prescribed.1 The non-medical 
use of pharmaceuticals is a unique category of substance misuse in a 
number of ways, as the scale of the problem is largely unknown owing 
to lack of data. This is partly due to the existence of many gaps in the 
monitoring of their legal use for medical purposes. In addition, most 
studies on, and monitoring instruments for, substance abuse pertain 
to the use of illegal drugs or alcohol and tobacco.
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In brief
The Covid-19 pandemic has underlined the importance of 
effective responses to rapidly developing dangers to public 
health. Accurate data are the basis on which effective 
monitoring systems are built and trends derived to inform policy 
and to plan services. In recent years, new tools have been 
developed to gather and report drug-related information faster 
than the traditional routine systems. These tools have proved 
particularly useful in recent months, as innovative approaches 
have been needed to record and analyse the impact of the 
crisis on people who use drugs and on services.
Shortly before the introduction of restrictions to deal with the pandemic, 
Ana Liffey Drug Project published a Trendspotter study on street tablet use in 
Ireland. Trendspotting is a technique for assessing information using multiple 
research methods to rapidly expand knowledge on an area of interest. It 
has been developed by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). The report is summarised in this issue of Drugnet Ireland 
and is a fine example of collaborative working between non-governmental 
organisations and scientists to make valuable information on a pressing topic 
available quickly.
EMCDDA applied its trendspotting methodology to analyse the impact of 
Covid-19 and also produced reports on changes to the illicit drugs market. In a 
very different setting, the Evidence Centre of the Health Research Board (HRB) 
has refined its approach to research synthesis in the area of health services 
and policies and have several different products available for use in different 
situations. We were able to respond quickly to a request from the Department 
of Health to contribute to its rapid assessment of effects of the pandemic on 
the drugs situation. Our evidence brief is also summarised in this issue and uses 
the tools developed by the HRB to provide descriptive accounts of topics of 
immediate concern.
The response to the threat that Covid-19 presented to the vulnerable homeless 
population at the beginning of the pandemic was exemplary. The statutory and 
community and voluntary sectors worked in a highly efficient and coordinated 
way to ensure the safety of homeless people and people who use drugs. A 
number of those directly involved in this work have recorded this experience 
so that the lessons learned can inform future interventions.1 This is an excellent 
example of an innovative and responsive approach to research, using the 
knowledge gained from routine monitoring and other information resources to 
present a compelling narrative and provide a guide for the future.
There are lessons here for the broader research and monitoring environment. 
If we make full use of the information that is available, in excellent monitoring 
systems and the knowledge of practitioners and service providers, then the 
benefits for those who use these services will be immense. We’ve seen how the 
State can respond to a crisis when the evidence is clearly presented and there 
is the confidence and the capacity to use this evidence.
1 O’Carroll A, Duffin T and Collins J (2020) Saving lives in the time of COVID-19: case 
study of harm reduction, homelessness and drug use in Dublin, Ireland. London: 
London School of Economics and Political Science.  
https://www.drugsandalcohol.ie/32291/
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New Minister of State with responsibility  
for the National Drugs Strategy
On 2 July 2020 Frank  
Feighan TD for Sligo- 
Leitrim was appointed the 
Minister of State for Public 
Health, Well Being and 
National Drugs Strategy.
In the Republic of Ireland, converging signals of the ongoing 
non-medical use of pharmaceuticals (‘street tablets’) among 
clients of community-based, drug harm-reduction service 
agencies in Dublin were noted in 2018. These included 
significant levels of street tablet use among service clients, 
an increase in the prevalence of pregabalin in drug-related 
deaths data since 2015, and reports of online purchasing of 
tablets for the Irish market. In order to better understand 
these converging signals, the Ana Liffey Drug Project (ALDP), 
the School of Public Health at University College Cork, and 
the Health Research Board, with the support of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
conducted a Trendspotter study to examine patterns of use, 
markets, and harms related to street tablets in Ireland.2
Trendspotter study
A Trendspotter study is a rapid information assessment that 
uses multiple social research methods to explore a topic of 
interest or concern. The approach was developed and has 
been used by the EMCDDA since 2011 as a tool to complement 
other routine drug-monitoring methodologies.3 It has generally 
been utilised to explore emerging phenomena and new 
trends that are in their infancy and/or not covered by existing 
datasets. Undertaken between May and September 2019, 
the study commenced with a phase of data collection and a 
literature review, culminating in a 1.5-day expert presentation 
and facilitated groups meeting. The meeting consisted of a 
group of 11 experts from ALDP, the University of Limerick, 
Forensic Science Ireland, the Health Products Regulatory 
Authority, the Health Service Executive Addiction Services, 
Merchants Quay Ireland, An Garda Síochána, and addiction/
homelessness specialist general practitioners. Key findings from 
the report are discussed below.
Street tablet use
Experts provided data on use, changing consumption patterns, 
and availability, with a majority indicating that there has been 
an increase in the use and availability of street tablets in Ireland 
between 2016 and 2019. Drugs which are commonly misused in 
tablet or capsule form include benzodiazepines, Z-drugs, and 
gabapentinoids. The user groups identified included high-risk 
opioid users, prison populations, people with complex and 
multiple needs, and young people. Among these groups, the 
motivations for using street tablets included their intoxicating 
effects, to enhance desired effects from illicit substances, to 
help withdrawal symptoms, to improve sleep, and to reduce 
stress. Other potential reasons for use are that tablets are 
cheap to purchase and are easily available. Feedback from 
recent research as well as experts in this study highlighted 
the importance that culture plays in the availability and use of 
street tablets among communities. On a cultural level, there is 
an acceptance of the misuse of street tablets as part of normal 
life and behaviour. Doctors have the legal ability to prescribe 
these medications on a wide scale, which strengthens the 
idea that they are safe to use for long periods of time. Also, in 
addition to affecting local cultures, street tablet supply, trade, 
and distribution have become embedded in local economies, 
as people are selling, sharing, and swapping street tablets as a 
form of currency.
Street tablet markets
In terms of the importation of ready tableted products, the 
main sources appear to originate from the Indian subcontinent. 
However, as Ireland is not a transit country, identifying the 
origin of drugs being transported to Ireland can be difficult. 
Another possible avenue of availability cited was the healthcare 
system, with overprescribing resulting in the ability for 
individuals to sell unused tablets on the street. Online sources 
were also identified as a source of street tablet availability 
and that, through the internet and social media, distribution 
of benzodiazepines, Z-drugs, and pregabalin is much easier 
and wider-reaching. Insofar as routes to markets for tablets in 
Ireland are concerned, all of these sources are likely to play a 
part.
It is interesting to note that in terms of online purchasing, as far 
as prescription medications are concerned, the study noted 
that there are adequate sources available on the surface web 
to suggest that purchasers do not have to be sophisticated 
web users capable of operating on the dark web in order to 
purchase tablets online. There are many ‘online pharmacies’ 
where medications may be purchased without a prescription. 
As these sites do not have to be registered in Ireland, or store 
their stock here, it can be difficult for Irish regulators to assert 
authority over such enterprises. Concerningly, the study noted 
that the laboratory analysis of detained products demonstrated 
that medicines purchased online often contain too little or too 
much of the active ingredient. They have also been found to 
contain harmful or undeclared substances.
Street tablet harms
Data from the Irish Healthcare Pricing Office demonstrate 
an increase in the number of non-fatal self-poisoning cases 
involving benzodiazepines and antiepileptic and sedative-
hypnotic drugs between 2015 and 2018. Statistics from the 
National Drug-Related Deaths Index (NDRDI) also indicate an 
overall increase in the number of deaths involving alprazolam, 
zopiclone, and pregabalin. In particular, pregabalin-related 
deaths have risen year on year between 2012 and 2016, with an 
increase of 33% between 2015 and 2016 and an overall increase 
of 364% between 2013 and 2016 (see Figure 1). Concurrent with 
an increase in the number of drug-related deaths in Ireland 
involving benzodiazepines and antiepileptic and sedative-
hypnotic drugs, data from the NDRDI also show an increase 
in the number of poisoning deaths involving a combination of 
substances between 2004 and 2016 (see Figure 2). Experts who 
took part in the study indicated that polydrug use remains a 
consistent factor in the harms related to street tablet use and 
that the combined use of controlled substances and street 
tablets has contributed to an increase in drug-related deaths. 
In addition, the study found that from reports by Irish drug 









   











0 Trendspotter study   continued
harm reduction services and external studies indicate that 
individuals who misuse pharmaceuticals are taking (often much) 
higher than recommended doses and that a vast majority have 
a history of misuse or dependence on other drugs.
Conclusions
The study identified a number of issues which could help 
to manage the street tablet market. In terms of preventing 
leakage from the legitimate sources, a robust electronic 
prescribing system could help better control access, and might 
help prevent ‘doctor shopping’. However, it was also noted 
that care is needed not to inadvertently divert people to the 
street market to seek access to tablets. There is also a need 
to understand and be effective in addressing why individuals 
are using tablets in the first place, and therefore able to 
address the reasons why people have to access the tablet 
market. In this context, supporting medical professionals to 
better understand and be equipped to address the demand 
encountered is important, as is the need to get existing public 
health and harm reduction messaging into novel market spaces, 
such as the online environment.
Seán Millar
1 United Nations Office on Drugs and Crime (UNODC) (2011) The 
non-medical use of prescription drugs: policy direction issues. 
New York: United Nations.
2 Duffin T, Keane M and Millar SR (2020) Street tablet use in Ireland: 
a Trendspotter study on use, markets, and harms. Dublin: Ana 
Liffey Drug Project. https://www.drugsandalcohol.ie/31872/
3 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2018) Trendspotter manual: a handbook for the rapid 
assessment of emerging drug-related trends. Luxembourg: 
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Figure 1: Poisoning deaths in Ireland involving benzodiazepines and antiepileptic and sedative-hypnotic drugs: main specific drugs implicated, 
2010–2016
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Figure 2: Poisoning deaths in Ireland, by single/poly drugs involved, 2004–2016
Source: Duffin, Keane and Millar (2020)
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POLICY AND LEGISLATION 
HRB evidence brief 
on the response 
of drug services to 
Covid-19
Policy context
The Covid-19 pandemic presents particular challenges for 
people who are using drugs and for those providing services to 
vulnerable populations. In April 2020, the Drug Policy Unit at 
the Department of Health (DOH) established a rapid assessment 
group to look at the impact of the pandemic in Ireland. As part 
of this rapid assessment, DOH asked the Health Research Board 
(HRB) to prepare an evidence brief examining the situation in a 
number of comparable jurisdictions. This rapid evidence brief 
will help DOH put the Irish response to the Covid-19 crisis in 
an international context. The findings will enable a comparison 
with the situation in other countries and assist in identifying 
initiatives that may be relevant to the drugs situation in Ireland.
Research questions
The primary research question for the evidence brief is what 
approaches have been taken in Scotland; New South Wales 
(NSW), Australia; New York State (NYS); and British Columbia 
(BC), Canada to deal with the impact of the Covid-19 pandemic 
on people who use drug treatment and harm reduction 
services and other people who use drugs.
There are four sub-questions:
1 How has Covid-19 impacted on people who use drugs?
2 How has Covid-19 impacted on the demand for drug and 
alcohol services?
3 What guidelines and supports have been provided for drug 
and alcohol services in light of Covid-19?
4 How are drugs and alcohol services being restructured to 
meet clients’ needs in light of Covid-19, especially clients 
with complex needs and who are most vulnerable?
The evidence brief applied the four research questions to 
the situation in Scotland, NSW, NYS, and BC. These were 
chosen because they are developed economies and have 
been disrupted by the Covid-19 pandemic and because 
official documentation is available in English. They also have 
patterns of problem drug use similar to Ireland and provide a 
comparable range of treatment and harm reduction responses. 
The evidence brief also presents a summary of information 
available in Ireland and in other European Union (EU) countries 
to provide a context beside which findings from the four 
research jurisdictions can be read.
Question 1: How has Covid-19 impacted on 
people who use drugs?
When this research was being carried out, there was very 
little evidence available regarding the impact of the Covid-19 
pandemic. In early March 2020, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) began an 
investigative rapid assessment to monitor the impact of 
Covid-19 on the drugs situation in Europe and the responses 
to it. This assessment included a mini-web survey of people 
who use drugs but might not be accessing services. The first 
report from the EMCDDA study was published in May 20201 and 
some report findings from that and from an EMCDDA report on 
drug markets are presented in the evidence brief. Information 
on the situation in the four research jurisdictions was mainly 
anecdotal, apart from one survey undertaken in Scotland.
Ireland and European context
Data from the EMCDDA mini-web survey indicate that 
respondents in Ireland who used cannabis or cocaine more 
frequently (daily or almost daily) in the 30 days prior to the 
introduction of restrictions were much more likely to use drugs 
more frequently or to use greater amounts in one session than 
they had before. In answer to the question ‘In general, would 
you say you have used more or less illicit drugs, since the 
start of the Covid-19 epidemic in your country?’, 209 (33%) 
respondents replied less, 142 (22%) replied more, and 90 (14%) 
replied the same amount.
An EMCDDA study on drug markets2 found that disruptions to 
the supply chain were most evident at the distribution level, 
resulting in increased violence in some jurisdictions. Bulk 
movement of drugs through shipping has not been interrupted. 
Domestic production of cannabis has been disrupted and 
prices have increased. Alternative means of both acquisition, 
for instance, through online sources, and distribution, through 
the postal service and drops, have been reported.
New York State
The Drug Enforcement Administration (DEA), a federal body 
and lead agency for domestic enforcement of the Controlled 
Substances Act, reports that the price of street drugs has 
increased as distribution costs have risen. Since March, 
cannabis prices increased by 55%, cocaine prices by 12%, and 
heroin prices by 7%.
Scotland
The Scottish Drug Deaths Taskforce has received feedback 
from services and communities which suggests that service-
level provision of harm reduction services is being scaled back 
in some areas. Responses to the Crew survey3 in April suggest 
that there have been product shortages, less variety, poorer 
quality, and some price increases. Some respondents report 
an increase in unintended withdrawal symptoms as a result of 
reduced availability.
Question 2: How has Covid-19 impacted on the 
demand for drug and alcohol services?
There was little concrete information available to answer 
this question when the research was being conducted. The 
European context is described below with information from one 
of the research jurisdictions.
Ireland and European context
Many EU jurisdictions saw an initial decline in treatment 
demand attributed to restrictions on movements, reduced 
capacity in treatment services, and fewer referrals from the 
criminal justice system. Harm reduction services have reported 
an increase in demand for social support and increases in 
alcohol and benzodiazepine use as a result of higher levels of 
anxiety among service users. Generally, much of the increased 










   













There is anecdotal evidence that more stimulant users are 
coming into contact with services due to a reduced ability to 
source these drugs or due to changes to daily routine enforced 
by lockdown, leading to the realisation that their substance use 
is problematic. This includes more vulnerable stimulant users 
who may not have been previously visible to services.
Question 3: What guidelines and supports have 
been provided for drug and alcohol services in 
light of Covid-19?
This was the research question for which there was most 
evidence available. All of the health services in the areas 
covered responded very quickly to the situation with clear 
recommendations and generally a high degree of flexibility. 
The need to maintain access to opioid substitution treatment 
(OST) or opioid agonist therapy (OAT) for existing clients is a 
common theme and ensuring this has required a great deal 
of coordination and the development of innovative service 
and policy approaches. Variations in responses are somewhat 
determined by historical factors, the degree of autonomy 
accorded to local administrators of health services, and the 
degree to which a harm reduction ethos has been embedded. 
For instance, NYS followed guidelines issued by DEA, and the 
degree of independence, or willingness to innovate, at the 
state and city level seems to be less than in Vancouver or 
BC. Separate but compatible guidelines for OAT have been 
published by Vancouver Coastal Health,4 a regional health 
authority, and the British Columbia Centre on Substance Use 
(BCCSU)5 addiction. Health Canada provides the overarching 
direction for policy and health service delivery at the federal 
level.
Ireland and European context
In Ireland, guidelines on contingency planning from the 
Health Service Executive (HSE)6 recommend several actions, 
in particular for people who are unable to access services 
either through their own isolation or because services are not 
currently available. The process by which a clinical review for 
OST clients can be undertaken remotely (with video link or 
smartphone) is spelled out in detail in guidance documents. A 
number of options are available for a person in treatment who 
is isolating at home, including provision of sufficient doses for 
the duration of the self-isolation and provision of medication 
to family members or a driver or key worker. The guidelines 
provide advice regarding the secure storage of doses, general 
safety, medicines management policy, remote consultation, 
and record keeping.
OST treatment services in Ireland have continued. The use of 
eConsultation software and the delivery of medication have 
ensured people in isolation can continue their treatment. 
Clinics have implemented social distancing measures and 
provided people with letters stating the date and time of their 
appointment to ensure permission to travel during the period 
of restricted movement. Recovery groups are now provided 
online in several areas.
The wait for methadone treatment has been reduced from 
12 weeks to three days. Benzodiazepine prescriptions have 
increased to enable easier stabilisation of drug use during 
isolation. Resources have been provided to support cocooning 
and isolation of vulnerable homeless people. Outreach services 
have been active in providing information on Covid-19 to clients 
when delivering needle and syringe exchange services.
Temporary amendments to the Medicinal Products and Misuse 
of Drugs legislation are designed to ensure that patients can 
continue to access their ongoing treatment and ‘regular’ 
medicines during the ongoing emergency and to assist in easing 
the additional burdens on prescribers and pharmacists arising 
from the pandemic. The amendments allow for the electronic 
transfer of prescriptions between doctors and pharmacies 
and remove the need for a paper equivalent. The legislation 
also extends the validity of prescriptions from six to nine 
months and enables pharmacists to make additional supplies 
of prescription-only medicines to patients from an existing 
prescription. This additional authority to pharmacists must only 
be used where, in the pharmacist’s professional judgement, 
continued treatment is required, and it is safe and appropriate 
to make an additional supply.
Several international organisations have produced guidelines 
for drug services and these have been adapted or added to 
by services in many countries. Most guidelines include advice 
on take-home doses, moving from supervised consumption 
of substitution medication, prescription delivery, remote 
counselling, and initiation of treatment. German guidelines7 
point out that OST patient must be visited by a doctor when a 
prescription for self-administration is being delivered.
While these guidelines are welcome, many jurisdictions have 
reported challenges in starting treatment for new clients. 
Detoxification has been discontinued or significantly curtailed 
in most jurisdictions. The need to maintain access to OST 
for existing clients is a common theme and ensuring this has 
required a great deal of coordination and the development of 
innovative service and policy approaches. There is concern 
around the greater danger of overdose as some services 
prescribe larger take-home packs of OST. The effort to 
accommodate those entering or seeking to maintain OST may 
have the effect of making less resources available for those who 
use other drugs. Telemedicine, by phone or video, has largely 
replaced face-to-face contacts. There are obvious benefits 
to using these technologies as contacts with clients can be 
maintained and counselling sessions continued. However, there 
have been difficulties in persuading clients to engage with 
remote technologies and the inability of service users to access 
the devices needed to use them.
New York State
At the federal level, DEA has partnered with the Substance 
Abuse and Mental Health Services Administration (SAMHSA) 
to ensure authorised practitioners may admit and treat new 
patients with opioid use disorder. DEA states that practitioners 
may prescribe controlled substances to patients using 
telemedicine without first conducting an in-person evaluation 
during this public health emergency. Patients presenting 
with respiratory symptoms should be evaluated by a medical 
provider who will decide on a safe number of take-home doses, 
up to 28 days of medication, taking into consideration the 
patient’s stability in treatment and ability to safely store and 
protect the medication.
Federal law requires a complete physical evaluation before 
admission to an opioid treatment programme (OTP). Under 
exemptions to the Controlled Substances Act, practitioners may 
prescribe controlled substances to patients using telemedicine 
without first conducting an in-person evaluation. New patients 
treated with buprenorphine can be assessed using telehealth 
Covid-19 evidence brief   continued
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systems, but this exemption does not apply to methadone 
patients, who are not permitted to receive escalating doses for 
induction as take-home medication.
Patients who only have access to one take-home medication 
or do not use this service should be considered for a staggered 
take-home schedule. Patients can still be evaluated frequently 
and do not receive more than two days of take-home 
medication at any one time. Based on the more favourable 
safety profile of buprenorphine, programmes should seek to 
maximise the ability of patients to take their buprenorphine at 
home during the Covid-19 crisis.
As there are no time-in-treatment take-home regulatory 
requirements for patients being dispensed buprenorphine, 
patients should be evaluated for flexible take-home doses as 
clinically warranted. An OTP can provide delivery of medication 
to an individual patient’s home or to another controlled 
treatment environment. A responsible adult can serve as a 
designated other or surrogate to pick up an OTP patient’s 
medication.
SAMHSA urges providers to consider utilising benzodiazepines 
for individuals with alcohol use disorder where they believe 
there would not be a benefit from administration of 
anticonvulsant medications. Medications such as gabapentin, 
topiramate, or carbamazepine are useful in preventing 
seizures related to alcohol or benzodiazepine withdrawal. 
These medications also possess a much lower abuse potential. 
Limited doses of benzodiazepines might be considered for 
specific symptom relief for a short duration (several days).
British Columbia
Specialised substance use services, including withdrawal 
management services, are delivered primarily through 
five regional health authorities, the First Nations Health 
Authority, and the Provincial Health Services Authority. 
Canada’s Controlled Drugs and Substances Act 1996 has been 
amended to permit pharmacists to extend, renew, and transfer 
prescriptions and verbally prescribe controlled substances, 
which can be delivered by pharmacy technicians to a private 
address, not necessarily that of the patient receiving the 
prescription. Changes of pharmacy regulation allow emergency 
supplies to patients with expired prescriptions and the 
provision of carries to reduce exposure to Covid-19.
BCCSU general prescribing guidance advises general 
practitioners to send OAT prescriptions to pharmacies with the 
capacity to deliver, or deliver medications directly to patients, 
weekly if necessary, with advice on storage. In order to reduce 
the risk of withdrawal, exposure to Covid-19, and exposure 
to a limited and toxic drug supply, BCCSU recommended 
replacing illicit and licit products with prescribed or 
regulated substances. For patients who use opioids, BCCSU 
recommended offering OAT or increasing doses or providing 
carries for existing current patients. Co-prescription of oral 
morphine will help to reduce withdrawal symptoms.
For patients using street opioids in addition to their OAT or 
who decline OAT, prescriptions should be made according 
to current use and patient preference as well as clinical 
judgement to select appropriate medications and dosage. Dose 
and medication will depend on whether or not patients are 
being co-prescribed OAT and patterns of substance use. The 
dose can be adjusted over time, with the goal of the person 
being comfortable and not needing to access the illicit drug 
market. Witness ingestion is not required and the prescription 
of up to seven days’ supply of carries, preferably in blister 
packages, can be considered where clinically appropriate. 
Similar guidelines apply to the prescription of buprenorphine/
naloxone and patients can receive longer duration carries 
because of the reduced risk of overdose. Micro-induction may 
be considered for individuals transitioning from another OAT 
medication to buprenorphine/naloxone, to avoid the need for 
a washout period and moderate withdrawal to be reached prior 
to induction.
Similar guidelines are provided for prescribing sustained-
release oral morphine and methadone, and guidance on 
injectable OAT (hydromorphone and diacetylmorphine) is 
forthcoming. As with other OAT medication, prescribing will 
depend on patient stability and their capacity to store. In all 
cases, clear communication with pharmacies is essential. Risk 
of overdose, diversion, or risks to household members must be 
carefully considered when deliveries or extended carries are 
being considered. Telehealth is especially recommended for 
use when dealing with patients accessing OAT.
For those at risk of severe withdrawal from alcohol, BCCSU 
recommended inpatient withdrawal management, which may 
include prescribing benzodiazepines. For those declining this 
treatment, advice on withdrawal, including safely reducing 
alcohol and accessing alcohol, should be given. If the patient 
is at low risk of complicated withdrawal, prescribers should 
consider gabapentin and/or clonidine and/or carbamazepine. 
BCCSU recommended psychostimulants, such as Dexedrine 
and methylphenidate, as part of replacement therapy for those 
with stimulant use disorder. The prescription must come with 
advice regarding possible worsening of symptoms and side-
effects of medication. For users of illicit benzodiazepines, 
BCCSU recommended relatively low doses of clonazepam or 
diazepam with up-titration as needed.
A Health Canada class exemption enables a flexible approach 
to supervised consumption services that may include drug 
checking and virtual supervision of drug consumption. The 
British Columbia Centre for Disease Control (BCCDC) has 
published an overdose prevention protocol in the context 
of Covid-19, taking account of the change in regulations and 
making recommendations on safer injecting, take-home 
naloxone kits, and observation of consumption in any health or 
social service sector environment.
Scotland
Responsibility for the National Health Service (NHS) in Scotland 
is a devolved matter and rests with the Scottish Government. 
The Scottish Drugs Forum works with policymakers, service 
planners and commissioners, service managers and staff as 
well as people who use or have used services to ensure service 
quality and evidence-based policy and practice. The forum has 
published comprehensive guidance to help treatment services 
plan, manage, and deliver services for people who use drugs 
during the Covid-19 pandemic.
Supervision of self-isolating OST patients can be relaxed, and 14 
days of take-home medication can be provided where needed, 
and arrangements made for home delivery. The patient can 
nominate a representative to collect and deliver medication, 
including controlled drugs. Provision should be made to ensure 
medication is still available should a pharmacy be closed. 









   












Take-home supplies of safe injecting equipment for up to 14 
days should be encouraged. Take-home supplies have largely 
replaced daily supervised dispensing and there is guidance 
around managing home delivery. Priority should be given to 
those seeking treatment as a result of the supply reduction of 
heroin. Doorstep titrations – of methadone or buprenorphine, 
depending on the patient’s circumstances – using existing 
protocols are used by some services, and guidelines on this 
approach are provided.
Serious shortage protocols legislation may be enacted to 
allow pharmacists to supply branded products and different 
preparation strengths, and methadone tables not currently 
licensed may be used if an oral solution is not available. 
Conversion to various formulations of buprenorphine is 
possible with caution of the risk of precipitated withdrawal 
and micro-dosing to support a slower transition. Injectable 
buprenorphine and modified-release preparations may be 
considered.
For those with alcohol use disorders, the priority should be to 
avoid the abrupt changes in alcohol consumption patterns that 
might trigger serious withdrawal symptoms. Relapse prevention 
medications, such as acamprosate, disulfiram (Antabuse), 
naltrexone, and baclofen, can be crucial to recovery, and 
prescriptions should be maintained. It has been reported 
that more vulnerable stimulant users are seeking treatment. 
While psychosocial interventions are typical for problematic 
stimulant use, the guidelines note the harm reduction approach 
being pursued in Canada. Scotland has decided to allow the 
prescribing of benzodiazepines to those at risk of harm, while 
acknowledging the absence of peer-reviewed and established 
evidence-based guidance on benzodiazepine prescribing. While 
it is not possible to estimate tolerance when illicitly produced 
benzodiazepines are being used, estimated equivalents of 
prescribed drugs serve as a guideline.
New South Wales
The federal minister for health administers Australia’s national 
health policy, and state and territory governments administer 
elements of healthcare within their jurisdictions. State 
governments have responsibility for funding and managing 
community and mental health services, which include 
drug and alcohol services. A national guidance document 
suggests sublingual buprenorphine, with transfer to depot 
buprenorphine, as it requires less clinical monitoring and 
a shorter period of supervised dosing. Patients should be 
categorised into high, moderate, or low risk groups, which 
will determine the dosing regimen. Guidance is provided on 
collection and delivery of medication for those in isolation, 
including the selection of the agent responsible. Prescribers 
should advise all OAT patients to obtain take-home naloxone as 
a safety precaution.
Question 4: How are drugs and alcohol services 
being restructured to meet clients’ needs 
in light of Covid-19, especially clients with 
complex needs and who are most vulnerable?
New York State
The Office of Addiction Services and Supports (OASAS) states 
that an inability to keep take-home doses of medication 
safe due to a chaotic living situation (e.g. certain types of 
homelessness) would be grounds for patients being deemed 
ineligible for an emergency, take-home exemption. For these 
patients who, for safety reasons, need to continue daily dosing, 
every precaution should be made to limit exposure to patients 
possibly symptomatic for Covid-19, as well as to older and/or 
medically fragile patients. However, OASAS do not provide any 
further guidance in relation to this.
British Columbia
Vancouver Coastal Health published comprehensive guidance 
for implementing and operating Covid-19 facilities for homeless 
and under-housed residents who are unable to self-isolate. 
They identify that long-term substance users are at high risk 
from complications of Covid-19 and that their needs should be 
addressed.
Scotland
In February 2020, some 26% of the prison population were 
receiving a daily OST, which is difficult to sustain under Covid-19 
due to efforts to comply with social distancing and elevated 
rates of staff absence. The Scottish Government guidance 
recommended transferring appropriate patients receiving 
daily OST via oral methadone or solid dose buprenorphine to 
monthly injections of slow-release buprenorphine (Buvidal). 
It is essential that those leaving prison at risk of overdose are 
provided with naloxone on release. In addition to the existing 
intramuscular products already provided, work is underway 
to pilot the provision of intranasal naloxone to increase the 
numbers of people with naloxone in their possession on 
release. It was anticipated that 350–400 people under the 
scheme would be released from prison by the end of May 2020.
Guidance from Pathway, the leading homeless healthcare 
charity in the United Kingdom (UK), has been developed in 
a UK/English legal context, but is of use to those planning 
and delivering services in Scotland. The guidance states that 
patients with alcohol, drug, or nicotine addiction should be 
able to access a variety of approaches to prevent withdrawal, 
with input from specialist addiction services to minimise their 
need to leave isolation.
New South Wales
The NSW Department of Communities and Justice has 
developed guidance for providers that are delivering 
services for people experiencing homelessness during 
Covid-19. It advises that consideration should be made 
in relation to assisting clients in accessing ‘take-away’ 
supplies of replacement drug therapies (i.e. methadone and 
buprenorphine) in consultation with the local health network/
methadone clinic.
Discussion
There was limited information on the impact of the Covid-19 
pandemic on people who use drugs or on the demand for 
treatment services. The guidance for treating new patients 
entering OTPs differed by region. NYS recommended treating 
with buprenorphine where possible, as it can be prescribed by 
telemedicine without first conducting an in-person evaluation. 
However, this does not apply to patients starting methadone. 
Buprenorphine was also recommended by NSW, followed by 
transfer to depot buprenorphine after one week. Scotland 
stated that either buprenorphine or methadone may be 
used but titration onto methadone is often safer when the 
medication can be provided on a daily supervised dispensing 
regime from a pharmacy. BC recommended considering 
buprenorphine but also provided comprehensive guidance for 
all other potentially suitable medications. The reasons cited 
Covid-19 evidence brief   continued
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for using buprenorphine include its superior safety profile and 
reduced risk of overdose and diversion.
In response to the Covid-19 pandemic, each region has 
introduced changes to their protocols on providing take-away 
doses (TADs) to patients and on delivering medications. This 
has led to patients being allowed to receive an increased 
number of TADs. While NYS and NSW are prescriptive in their 
guidance around TADs, provision of TADs in BC and Scotland 
appear to be at the discretion of the prescriber and based 
on the individual patient. In circumstances where patients 
cannot access their medications, in each region it is now 
permissible for pharmacies and treatment programmes to 
deliver medication, or, alternatively, nominated persons are 
allowed to collect medication on the patient’s behalf. Given 
the relaxation of the rules around prescribing controlled 
medications, the risk of overdose was cited, with BC, Scotland, 
and NSW all recommending that patients be provided with 
take-home naloxone. Scotland recommended offering naloxone 
with injecting equipment provision transactions, while BC has 
allowed the establishment of temporary spaces that comply 
with physical distancing within supervised consumption 
services.
Regarding other substance use, BC has published the most 
comprehensive guidance. It recommends replacing illicit 
and licit products with prescribed or regulated substances. 
It has also published a detailed pharmacotherapy protocol 
for opiates, alcohol, benzodiazepines, and stimulants. In 
relation to alcohol use, NYS, BC, and Scotland provide 
guidance on managing outpatient withdrawal and on the use 
of medication to do this. BC is the only area that has guidance 
on how to provide a managed alcohol programme and on 
how to ensure that patients have access to an adequate 
alcohol supply to prevent severe withdrawal complications. 
For benzodiazepine use, NYS, BC, and Scotland recommend 
prescribing benzodiazepines, with BC providing more detailed 
guidance on how to manage these clients. Just BC and Scotland 
provide guidance for stimulant use, which in fact differs: BC 
recommends prescribing Dexedrine or methylphenidate 
for stimulant users, while the Scottish guidance does not 
recommend the use of these off-licence drugs.
There was some guidance in BC, Scotland, and NSW in relation 
Covid-19 evidence brief   continued to vulnerable people or those with complex needs. BC and NSW provided guidance for services dealing with people 
who are homeless; this guidance mainly related to ensuring 
they could access and store medications. Scotland was the 
only region to provide guidance in relation to prisons. It 
recommended transitioning those receiving daily supervised 
OST to Buvidal, which is a long-acting buprenorphine depot 
injection, for people serving six months or longer. This was to 
achieve a rapid reduction in the need for daily contact with 
NHS front-line and prison staff. It also recommended that 
those leaving prison be provided with naloxone.
Brian Galvin and Deirdre Mongan
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Gender and drug 
policy
The mission of the Pompidou Group of the Council of Europe is 
to contribute to the development of multidisciplinary, innovative, 
effective and evidence-based drug policies in its member states.1 
Since the late 1980s, it has worked to support the integration of 
a gender dimension into drug policies and has delivered on a 
number of activities in this area of policy.2 The group is currently 
running a project on implementing a gender approach in different 
drug policy areas: from prevention, care, and treatment services 
to law enforcement and the criminal justice system. It is based on 
an understanding that the gender dimension includes women, 
men, transgender, and intersex people. The Irish team taking part 
in this project is made up of representatives from academia, the 
Department of Health, and drug services.3 As part of their work, 
they published a paper on gender and Irish drug policy in April 
2020.4
Aims of Pompidou project
The overall aims of the Pompidou Group’s project are to:
• Carry out an analysis of needs and draw up proposals for 
feasible actions and interventions to be undertaken by 
different stakeholders (including government and non-
governmental agencies) to effectively integrate different 
gender perspectives of persons who use drugs in planning, 









   












• Identify obstacles and barriers for accessing care and 
treatment and for introducing a gender dimension in drug 
policy, as well as ways to overcome them.
• Identify obstacles and barriers for the integration of gender 
approaches in drug law enforcement and the criminal 
justice system, as well as ways to overcome them.
• Provide a better understanding of when best to apply 
gender-neutral approaches, and when applying gender-
specific responses would be more appropriate.
Irish contribution
Morton et al.’s paper outlines the Irish situation in relation to 
five topics linked to these aims: gender in current drug policy; 
transgender and/or intersex persons within service delivery; 
stakeholders at national level; obstacles to the integration of a 
gender-sensitive approach; and benefits to society and health 
and wellbeing of target groups of adapting and implementing a 
gender-sensitive approach. Some of the findings are outlined 
below.
Gender and drug policy
Ireland’s current national drugs strategy, Reducing harm, 
supporting recovery (2017–2025),5 is described in the paper as 
marking a shift in Irish drug policy away from previous strategies 
that were ‘relatively gender-neutral’ (p. 3)4 to one which ‘attends 
extensively to the issue of women and substance use’ (p. 3).4 
Morton et al. outline the elements of the strategy that deal 
with gender, specifically noting four of the 50 strategic actions 
contained in the document – three relate to women specifically, 
while a fourth refers to the needs of the LGBTQI community.
1 There is a strategic action to ‘respond to the needs of women 
who are using drugs and/or alcohol in a harmful manner’, by 
increasing the range of wraparound community and residential 
services equipped to meet their needs and by developing 
interventions to address gender and cultural-specific risk 
factors for not taking up treatment (p. 42).5
2 There is a commitment to ‘expand addiction services for 
pregnant and postnatal women’ through seven developments, 
including strengthening links between addiction and maternity 
services (p. 43).5
3 Under the strategic action ‘to improve the range of problem 
substance use services and rehabilitation supports for people 
with high support needs who are homeless’, mention is made 
specifically of developing the provision of gender-specific 
stepdown services for women and their children progressing 
from residential rehabilitation treatment who are at risk of 
discharge into homelessness (p. 48).5
4 There is a strategic action that sets out to improve the 
capacity of services to accommodate the needs of people 
who use drugs and alcohol from specific communities. (p. 49).5
The authors note that there are neither gender-specific actions 
within the current drugs strategy in regard to prevention nor any 
specific considerations of transgender or intersex populations or 
risks for these populations. They describe any consideration of the 
needs and specialist supports for those who are transgender and/
or intersex in Ireland as being in ‘relative infancy’ (p. 5).
Gender and treatment
Drug treatment and intervention in Ireland is described as having 
evolved over the previous 15 years to a more gender role focus. 
The authors identify some changes made: including women in 
substance use treatment and intervention; developing gender-
specific services and interventions for women; and developing 
resources and responses within relevant ancillary services to 
meet the needs of women who use drugs. Table 1 outlines the 
gender-specific treatment and interventions for women in Ireland 
identified in the paper.
Gender and drug policy   continued
Service Intervention Host organisation
Ashleigh House Residential treatment for women and women  with children up to preschool age Coolmine Therapeutic Community
Saol Project
Gender-specific harm reduction, education, day 
programme, childcare provided up to preschool 
age
Saol Project
Aiséirí Céim Eile Residential secondary treatment programme, gender specific Aiséirí
Farnanes Residential treatment for women, gender specific Cuan Mhuire
Ocean View Residential treatment for women, gender specific Tiglin
Tabor Renewal & Fellowship House Residential secondary treatment programme, gender specific Tabor Group
Helping Women Recover Programme
This Limerick-based project works with women 
over the age of 23 who are clients of the Probation 
Service
PALLS
Specialist drug liaison midwives
The three maternity hospitals in Dublin have 
specialist midwives who work with pregnant  
women who use drugs
Health Service Executive
Table 1: Gender-specific treatment and interventions for women in Ireland
Source: Morton et al. (2020)
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Gender and the criminal justice system
The Pompidou Group is also interested in how gender is addressed 
within the criminal justice system. While this does not feature in 
Ireland’s national drugs strategy, Morton et al. note that the needs 
of women are identified in other related policy documents.6,7 They 
also identify issues arising within the courts and the prison system 
for women. For example, there are ‘specific risks for women 
involved within the criminal justice system, including a lack of 
housing supports on exit from prison, substance misuse within 
the prison itself, separation from children, and lack of integration 
supports on exit from prison’ (p. 5).
Obstacles to gender-sensitive approach
The authors outline a series of obstacles facing the adoption of 
a gender-sensitive approach to drug policy and interventions in 
Ireland. These exist at societal, policy, community, organisational, 
practitioner, and individual levels. For example:
• At a community level, women who use drugs experience 
stigma within their communities, which presents a major 
barrier to accessing supports.
• At an organisational level, funding streams can prevent 
the integration of a gender-sensitive approach either by 
not providing funding for gender-specific services or the 
services of the broader range of agencies that would be 
needed to meet the complex needs of women who use 
drugs.
• At the practitioner level, practitioners may not have 
been trained in ‘specialist responses that take account of 
gender within substance use patterns or trajectories, or in 
responding to women where there are complex issues and 
trauma histories’ (p. 10).
Gender mainstreaming
The authors offer support for the adoption of a gender-
mainstreaming approach to policy development in Ireland. This 
approach would mean each ‘drug policy proposal is assessed for 
its potential (unintended) positive and negative impacts across 
genders’ (p. 10), as well as a critical examination of the gendered 
norms and assumptions that underpin the proposals. The authors 
also report there is evidence in Ireland of an increasing focus 
on inclusion health and a patient and public involvement (PPI) 
approach to health issues. These along with other factors suggest 
an environment that might be more conducive to a fully gender-
sensitive approach to policy and service development evolving in 
Ireland. The authors conclude:
Gender and drug policy   continued Key within the Irish context will be the leveraging off the current developments within social inclusion based 
health, PPI, participative [national drugs strategy] 
structures and existing innovation in gender responsive 
intervention and treatments in order to further advance 
gender mainstreaming within drug policy, which may 
ultimately address some of the key individual issues 
such as stigma and shame in regard to gender and 
substance use. (p. 10)
Project output
Morton et al.’s paper is an output of the first phase of this broader 
project by the Pompidou Group. The final output of the project is 
expected to be a handbook for practitioners and decision-makers. 
It will contain a set of principles and practical examples that 
provide concrete guidance for implementing a gender approach 
in planning and delivering prevention, care, and treatment services 
for people who use drugs. It will also provide guidance for law 
enforcement agencies on the practical integration of gender 
approaches in their work. The project is in its early stages and due 
for completion in October 2021.
Lucy Dillon
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Launch of UBU Your 
Place Your Space
UBU Your Place Your Space is a new, targeted youth-funding 
scheme launched by the then Minister for Children and 
Youth Affairs, Dr Katherine Zappone TD, in December 2019.1 
It targets young people who are marginalised, disadvantaged, 
or vulnerable, and aims to provide services that support 
them. These include services that cover health, education, 
employment, and social connectedness. It combines four 
pre-existing overlapping schemes, including the Young 
People’s Facilities and Services Fund and the local drug task 
force projects. The scheme explicitly supports the delivery of 
action 1.2.8 in the National Drugs Strategy: to improve services 










   













In 2014, the Department of Children and Youth Affairs (DCYA) 
published Value for money and policy review of youth 
programmes.2 It reviewed programmes targeting at-risk 
youth that share similar objectives and target similar groups 
of young people – including a focus on those living in areas 
characterised by problem drug use, educational disadvantage, 
criminal activity, unemployment, and homelessness. Preventing 
the onset of or reducing drug taking is a common focus of the 
programmes. While recognising the value of the programmes, 
the review called for their ‘significant reform’ (p. 10) and made 
a set of recommendations to this end.3 Since the review, work 
has been ongoing at DCYA to implement its recommendations. 
It undertook an extensive programme of work, including 
reviewing evidence and engaging stakeholders to inform the 
development of this single funding scheme: UBU Your Place 
Your Space.
UBU Your Place Your Space
Mission and vision
Mission: To provide out-of-school supports to young people in 
their local communities to enable them to overcome adverse 
circumstances and achieve their full potential by improving 
their personal and social development outcomes.
Vision: All young people are enabled to realise their maximum 
potential, by respecting their rights and hearing their voices, 
while protecting and supporting them as they transition from 
childhood to adulthood.
Values
• Young people are free to participate in a wide range of 
quality activities.
• Provision is rights based and young person-centred.
• Young people are empowered to reach their full potential.
• Relationship building is key.
• There is clarity of purpose.
• Projects are maximised by promoting efficiency and 
effectiveness.
Funding strands
• Strand A provides funding for the direct provision of youth 
services.
• Strand B provides funding to support the access of young 
people to existing youth facilities.
• Strand C provides funding for capacity building.
Lucy Dillon
1 For more information on the scheme, visit the designated website: 
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2 Department of Health (2017) Reducing harm, supporting recovery: 
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3 Department of Children and Youth Affairs (2014) Value for money 
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Launch of UBU Your Place  
Your Space   continued
PREVALENCE AND CURRENT SITUATION
Qualitative insights 
into pregabalin use 
among individuals 
in opioid agonist 
treatment
Recent research and reports have highlighted the drug 
pregabalin due to its potential for dependence and abuse, and 
an increase in pregabalin-related overdose deaths in several 
European countries. As a prescription-only central nervous 
system (CNS) depressant analogue to gamma-aminobutyric 
acid (GABA), it is used for an array of conditions, including 
neuropathic pain, epilepsy, generalised anxiety disorder, and 
fibromyalgia.1 In a 2020 study published in Heroin Addiction 
and Related Clinical Problems, Brennan and Van Hout present 
qualitative insights into the experiences of patients in opioid 
agonist treatment (OAT) with pregabalin.2 The authors selected 
OAT patients as their study population because of their 
increased risk for problematic use of pregabalin and overdose.3 
Though related research in Ireland is sparse, international 
evidence has demonstrated that using pregabalin leads to the 
development of tolerance and withdrawal symptoms when 
ceased. The combined use of both opiates and pregabalin as 
two CNS depressants, while highly prevalent, has been shown to 
increase the risk of overdose and death.4 The current study was 
the first in Ireland to capture the experiences of OAT patients 
using pregabalin.
Methods
The qualitative descriptive study utilised one-on-one semi-
structured interviews. Participants were recruited from a 
service offering OAT and harm reduction in Dublin. To be 
eligible, participants had to be both current or former OAT 
patients and current or recent users of pregabalin. Of 15 
participants, nine were male and six female, ranging in age 
from 25 to 45 years. Data were analysed using thematic analysis 
assisted by NVivo 12 software. Having finalised the thematic 
framework, one researcher performed a participant check to 
ensure the accurate reflection of participants’ views.
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Key findings
• Use patterns: One-half of participants were initially 
prescribed pregabalin, predominantly for pain. The others 
first consumed pregabalin after receiving it from peers. 
For many participants, being part of a polydrug use/‘tablet 
taking’ culture and a history of using benzodiazepines 
or Z-drugs often preceded pregabalin use. Participants 
recounted combining pregabalin with substances such 
as methadone, benzodiazepines, and Z-drugs, and with 
stimulants such as crack cocaine to ‘come down’. Many 
stated consuming more than 1000 mg daily, with doses 
ranging from 800 mg to 6000 mg. Most took pregabalin 
orally, but none reported injecting, given its connotation 
with past heroin use.
• Motivators: The reasons for consuming pregabalin included 
the self-regulation of negative emotions and enhancement 
of sociability and confidence. Participants specifically 
stated using pregabalin to numb distress and underlying 
psychological issues such as trauma.
• Side-effects: Examples of undesirable side-effects 
mentioned were losing consciousness or control and 
behaviours such as shoplifting or aggression due to feeling 
‘invincible’.
• Sourcing routes: Strategies included approaching 
multiple doctors, exaggerating symptoms while seeking 
prescriptions, buying street pregabalin (also through social 
media), or diverting legitimate prescriptions from their 
network.
• Role of medical professionals: While some described 
doctors as gatekeepers to sourcing pregabalin, multiple 
participants received it from doctors or pharmacists 
illegitimately, filling prescriptions early or selling 
prescriptions.
• Detoxification and withdrawal symptoms: One 
participant recounted experiencing very severe physical 
and psychological withdrawal symptoms while detoxing 
from pregabalin at home. Another reported undergoing 
a medically supervised detox. Several other participants 
described psychotic symptoms and suicidal ideation during 
pregabalin withdrawal consistent with previous descriptions 
in the literature.
• Combination with opioids: The data provided some 
insights into the popularity of combining opioids with 
pregabalin. Participants reported using it to manage 
withdrawal symptoms from opioids and finding it superior 
to other substances. Use of pregabalin was also explained 
with its similarity in effect to opioids, specifically heroin. 
Additionally, pregabalin was described as strong in its effect, 
and therefore attractive to those with built-up tolerance.
• Harm perception and reduction: Participants were alert 
to the risk of overdose, often due to personal experiences, 
and reported using indigenous harm reduction strategies, 
such as decreasing consumption and not buying counterfeit 
Lyrica.
Pregabalin use   continued
Individual risk factors
Self-regulation of  
negative affect
Management of opioid  
withdrawal symptoms
Chronic pain
Lack of harm reduction  
resources
Systemic risk factors
Need for trauma-informed  
services
Lyrica rescheduling  
considerations
Need for enhanced public  
health awareness campaigns  
re: overdose and polydrug  
use
Figure 1: Risk factors for problematic pregabalin use in an OAT patient sample in Dublin
Community risk factors
Need for vigilant GP  
prescribing and pharmacy  
dispensing
Insufficient risk assessments  
and patient reviews in  
vulnerable populations
Insufficient consideration  










   













Based on the participant responses, Brennan and Van 
Hout conceptualise the consumption of pregabalin among 
service users receiving OAT within a socio-ecological model, 
reflecting interacting risk factors on the individual, community, 
and systemic levels (see Figure 1). They extrapolate several 
recommendations for policy and healthcare service delivery 
from participants’ accounts.
Given the participants’ worrying descriptions of malpractice, 
Brennan and Van Hout emphasise the need for monitoring 
pregabalin prescriptions and for doctors and pharmacists 
to carry out risk assessments considering OAT patients’ 
vulnerability to pregabalin dependence, reduce off-label 
prescribing, and choose alternatives to pregabalin for pain 
relief.
The authors also call for increased healthcare support for 
OAT patients using pregabalin, such as trauma-informed 
interventions, medical supervision, and vigilance to psychiatric 
symptoms during pregabalin detox, harm reduction measures, 
and information campaigns.
Pregabalin use   continued The study’s findings should be viewed in light of several methodological limitations, including the small sample, single 
study location, and potential recall bias. Considering the 
prevalence of polydrug use, statements about the effects of 
pregabalin should be interpreted with caution.
The study nonetheless provides important first insights into the 
risk factors for pregabalin use among OAT patients as an at-risk 
group, and features recommendations for policy and health 
service responses grounded in qualitative data.
Britta Thiemt
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Inspector of Prisons 
annual report, 2018
In December 2019, the Minister for Justice and Equality 
published the eight annual report of the Office of the 
Inspector of Prisons.1 Under section 32 of the Prisons Act 
2007, the Inspector of Prisons is required to submit a report 
to the Department of Justice and Equality outlining how the 
inspector’s functions were carried out during the preceding 12 
months. This was the first annual report prepared by Ms Patricia 
Gilheaney who was appointed inspector in May 2018.
Office of the Inspector of Prisons
The Office of the Inspector of Prisons (OIOP) is a statutory 
body launched under the Prisons Act 2007 to carry out regular 
inspections of Irish prisons.2 The main mission of the OIOP 
is ‘supporting excellence in both delivery and outcomes 
in Ireland’s prisons through an independent programme 
of inspections and investigations’.3 The work is centred on 
several values, such as ‘independence and impartial; human 
rights focused; transparent and collaborative; capable and 
systematic’.3
While the frequency of prison inspections is not specified in the 
legislation,2 according to international best practice inspections 
are carried out every three years.1 The main activities to be 
carried out by the Inspector of Prisons include:
• Regular inspection of all Irish prisons (n=13)
• Investigations of deaths arising in custody and on temporary 
release from prison
• Investigations requested by the Minister for Justice and 
Equality into how a prison is managed or functions
• Receive and respond to prisoners’ letters
• In accordance with Rule 57B of the Prison Rules,4 the OIOP 
should receive:
-  Notifications within seven days of a complaint being 
received by the prison governor
- Copies of decisions for not carrying out investigations 
into complaints that have no foundation or do not meet 
criteria outlined in the Prison Rules
- Copies of investigation team reports and interim 
reports
- Letters from complainants who are dissatisfied with the 
outcome.
The OIOP role does not include investigating or adjudicating 
over individual prisoner complaints but may examine reasons 
for complaints when performing this role.
Review of operational structure and resources
An external review of OIOP operational structure and resources 
was submitted to the Minister of Justice and Equality in 
December 2018. It acknowledged the ongoing growth, progress 
of operating models and business processes, and the hard work 
and dedication of staff within the OIOP. Nonetheless, several 
identified areas illustrated that the OIOP was not meeting its 
statutory role in accordance with international best practice. 
For example:
• Only three prisons were inspected in the previous five 
years.
• 50% of prison estates were not ‘formally’ inspected since 
the OIOP was initiated 10 years ago.
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• Due to insufficient resources, no programme of announced 
or unannounced inspections was made.
• Processes were not aligned to international ‘good practice’ 
(p. 6).
• The legal framework of the Prisons Act 2007 was deemed to 
lack clarity and comprehensiveness.
• There was insufficient funding of the OIOP.
While the report concluded that the OIOP was not ‘fit for 
purpose’ (p. 7), it acknowledged the intentions of the OIOP to 
develop:
• A comprehensive and ongoing programme of inspections
• Strong and reliable business processes based on 
international best practice
• A network of expert delivery partners and advisors
• A properly resourced inspectorate.
Due to the level of work that had been anticipated in 2019, 
the first inspection was not expected to take place until 2020. 
The intention was to conduct the inspection in such a way that 
supported collaborative learning, whereby other prison estates 
would learn how the new inspection regime was to be carried 
out. This first inspection was deemed vital to embedding a new 
quality standard and tone in the work of a revamped prisons 
inspectorate (p. 7).
Overview of 2018
Since the appointment of Ms Gilheaney in May 2018, the OIOP 
has been involved in several activities. For example: prison 
visits; the prisoner complaints system; letters from prisoners; 
investigations; and the Inspection of Places of Detention Bill 
Draft Scheme 2014.
Prison visits
Between May and July 2018, prison familiarisation visits were 
carried out with the aim of seeing the prisons and meeting 
prisoners and prison staff. While these visits were not formal 
inspections, several areas of concern were identified. These 
involved safety (protection, solitary confinement/restricted 
regimes, overcrowding, broken windows, and contraband); 
prisoner health and provision of appropriate services; 
rehabilitation; equity and women prisoners; professionalism of 
staff; and chaplaincy.
Prisoner complaints system
In 2018, some 79 category A complaints relating to nine prisons 
were reported to the OIOP. Analysis of all complaints was 
unachievable due to issues around submission of incomplete 
returns.
Letters from prisoners
Overall, the OIOP received 71 letters from prisoners in 2018. The 
highest number of complaints was received from the Midlands 
Prison (n=13) and Mountjoy Prison (n=13). The lowest number 
was received from Cork Prison (n=1) and the Dóchas Centre 
(n=1).
Investigations
In total, 21 death-in-custody investigations were completed 
and submitted to the Minister in 2018. The Minister published 
15 death-in-custody reports from a three-year timeframe: 
2016 (n=1), 2017 (n=10), and 2018 (n=4). In addition, a further 
preliminary investigation was requested by the Minister in 
response to allegations of misconduct by the Irish Prison 
Service reported in the Irish Examiner.
Inspection of Places of Detention Bill Draft Scheme 2014
Following an invitation by the Department of Justice and 
Equality, views on the Inspection of Places of Detention Bill 
Draft Scheme 2014 were submitted by the inspector to the 
department in September 2018.
Conclusion
The Irish Penal Reform Trust welcomed this report and looks 
forward to the OIOP publication of the Inspection Framework 
and Strategic Plan.5 It believes that these documents are 
essential to establishing the standards that will enable the OIOP 
to move towards meeting the inspector’s vision of a ‘world 
class’1,5 Inspectorate of Prisons.
Ciara H Guiney
1 Office of the Inspector of Prisons (2019) Office of the Inspector 
of Prisons annual report 2018. Dublin: Office of the Inspector of 
Prisons. https://www.drugsandalcohol.ie/31468/
2 Prisons Act 2007 Revised (2018). Available online at:  
http://revisedacts.lawreform.ie/eli/2007/act/10/front/revised/en/
html
3 Office of the Inspector of Prisons (2020) Office of the Inspector of 
Prisons. Available online at: https://www.oip.ie/
4 SI No. 252/2007 – Prison Rules 2007. Available online at:  
http://www.irishstatutebook.ie/eli/2007/si/252/made/en/print
5 Irish Penal Reform Trust (2019) Inspector of Prisons Annual Report 
2018 published. Dublin: Irish Penal Reform Trust. Available online 
at: https://www.iprt.ie/latest-news/inspector-of-prisons-annual-
report-2018-published/
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0 GYDP young people: 
response to Covid-19 
public health 
measures
On May 2020, the then Minister of State with responsibility 
for Youth Justice, David Stanton TD, launched a report that 
examined the response of young people participating in 
Garda Youth Diversion Projects (GYDPs) to the Covid-19 public 
health measures.1 The report was a collaboration between 
the Research Evidence into Policy, Programmes and Practice 
(REPPP) project based in the School of Law at the University 
of Limerick and the Department of Justice and Equality.1,2 




Youth justice workers (YJWs) (n=113) based in GYDPs across 
Ireland (n=104) were invited to complete an online qualitative 
survey. Data were collected between 23 April and 28 April 2020. 
Survey questions were centred on four areas (p. ii):
1 Young people in their GYDP and compliance with Covid-19 
public health measures.
2 Observed impacts for young people’s behaviours since 
measures were introduced.
3 How Covid-19 and restrictions affected GYDP work 
practices.
4 Requirements for front-line work with young people in 
GYDPs arising from Covid-19.
Where feasible, YJWs liaised with colleagues, local Gardaí, other 
community services, young people, and parents/caregivers.
There was a 97% response rate.
Survey focus
The characteristics of the survey participants included:
• Participating in GYDPs and having previous involvement in 
youth offending
• Being cautioned mainly with a criminal offence
• Representing a small cohort of Irish young people (approx. 
1 per 1000).
However, this population is consistent across Irish communities. 
In 2019, some 3,604 Irish youth were involved in GYDPs. YJWs 
were given autonomy on the prescribed population. The youth 
fell into three categories:
• Young people engaged with their GYDP (95%)
• Young people known in some capacity to the GYDP (64%)
• Young people in the locality covered by the GYDP (18%).
Findings
Compliance with Covid-19 public health measures
YJWs reported that most young people participating in GYDPs 
have been to ‘varying degrees’ in compliance with Covid-19 
public health measures.1 However, a minority of current and 
former participants were non-compliant.
Lifestyle changes and coping behaviours
Covid-19 health measures have resulted in greater reliance on 
social media and gaming to keep in touch with friends, mainly at 
night-time. YJWs acknowledged that due to changes in routine 
that engaging with young people has become more challenging. 
They report that in some cases family bonds have become 
stronger. However, for others, the measures have resulted in 
greater stress, giving rise to staying away from home. In some 
instances, adults have influenced non-compliant behaviour. 
YJWs have also reported that changes have negatively impacted 
on the young person’s mental health.
Prosocial behaviour
More than 50% of YJWs acknowledged that the majority of 
young people have engaged with prosocial behaviour and 
altruistic behaviour. Prosocial activities included:
• Self-care (education, physical, and mental health)
• Altruistic behaviour within family (e.g. caring for younger 
siblings)
• Altruistic behaviour external to family (e.g. checking-in 
on and doing jobs for the elderly, picking up litter, and 
fundraising) (p. iv).
Challenges for GYDP engagement with young people
GYDP engagement with young people is centred on a 
‘relationship-based’ intervention (p. v). While imaginative 
approaches were used to sustain engagement, several practical 
challenges emerged in attempts to do so (p. v). For example:
• Antisocial behaviour: Challenging antisocial behaviour and 
promotion of prosocial behaviour required the physical 
presence of the YJW and the young person. While YJWs 
overcame this problem using remote and online social 
media, this area is not addressed in policy and guidance.
• Technical IT support: Access to IT equipment and 
communication tools were needed by GYDP and by young 
people and their families.
• Financial pressures: Increased household costs were 
experienced by some families (e.g. food, cleaning products).
• Recreation/health: Recreation/health items were required 
(e.g. games for families and sanitisation equipment). 
• Tools, training, and guidance: These were required 
remotely in areas of education, mental health, and parent 
and family support.
• Funder support: Funder support was required (e.g. budget 
security and return to work guidance).
• Targeted re-engagement: Limitations of remote working 
were acknowledged, particularly with vulnerable young 
people, and targeted re-engagement was required.
Study limitations
The main limitations acknowledged by the authors included:
1 Observations of behaviour were only reported by YJWs 
participating in the survey.
2 The survey population represented a small cohort of young 
people in Ireland and in individual communities.
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Conclusion
Minister Stanton commented that he was proud that young 
people were involved in prosocial behaviours and activities 
during Covid-19. He believes that these actions illustrate that 
these young offenders are engaging with their communities and 
are attempting to turn corners, and it is vital that they continue 
to be supported. The Minister acknowledged the importance 
of this research and thanked the REPPP project and the 
Department of Justice and Equality for their collaboration.2
On 1 May 2020, a draft of the new Youth Justice Strategy was 
published online for consultation.3 The Minister called on all 
young people to contribute to this online consultation so that 
their voices can be heard.2,4
Garda Youth Diversion Projects   
continued
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to adverse childhood 
experiences and 
intergenerational 
patterns of domestic 
violence
In November 2019, Dr Sarah Morton and Dr Megan Curran 
of University College Dublin published the results of a Tusla-
funded study, Fostering understanding, empowering change: 
practice responses to adverse childhood experiences (ACEs) 
and intergenerational patterns of domestic violence.1
The aim of this study was to examine the experiences of 
women at the Cuan Saor Women’s Refuge, a domestic violence 
service in Co Tipperary. The focus was to identify the level of 
ACEs experienced by the women who accessed the service. 
Based on the ACEs routine enquiry process, trauma-informed 
responses (TIRs) to women’s childhood experiences and the 
intergenerational transmission of trauma were examined as well 
as the role of ACEs routine enquiry and intervention in relation 
to infant mental health (IMH), a key area of work for childcare 
workers within domestic violence (p. 10).
Adverse childhood experiences
The term initially appeared in an American study that examined 
childhood experiences, such as neglect and abuse, along with 
challenges at home and health and wellbeing.2 Seven types 
of ACEs were identified in the initial study: psychological, 
physical, or sexual abuse; domestic violence; or living with 
household members who abused substances, were mentally 
ill or suicidal, or had been incarcerated.2 As research in this 
area has grown, the list has expanded to include, for example, 
parental separation (p. 11).1 Even so, how specific ACEs have 
been operationally defined has not been consistent across the 
various studies.
A strong relationship has been demonstrated between the 
seven ACEs and chronic illness and death. Moreover, those 
reporting four ACEs or more were likely to experience several 
health risk factors when they were older.2 Figure 1 identifies 
areas that can be influenced by ACEs.
Intergenerational effects are also associated with ACEs. This 
means that when children with an ACE become adults, they are 
inclined to engage in behaviour that develops possible ACEs for 
their children. In children, ACEs are viewed as a form of trauma 
that result in a chronic state of stress. When this stress occurs 
during critical phases of their development, it can result in 
physiological changes, impacting brain development, immunity, 
and hormones. In addition, it prevents them from forming 
secure attachment bonds, which in turn impacts on their ability 









   











0 Adverse childhood experiences   
continued
Methodology
The study carried out at Cuan Saor Women’s Refuge was an 
action-research approach and involved a mixed-methods 
design using quantitative and qualitative data. It was carried out 
over nine months and broken down into three phases:
1 ACEs routine enquiry: Women who accessed the refuge 
over a three-month period anonymously completed a 
10-question ACEs questionnaire (n=60).
2 Qualitative data: These were collected via practitioner 
inquiry groups consisting of Cuan Saor staff (n=10). Three 
inquiry groups which lasted 90 minutes approximately were 
run every 4–6 weeks.
3 Interagency cooperative inquiry group (n=7): This 
examined the possibility of integrating ACEs into wider 
interagency work, particularly in the areas of IMH. This 
consisted of two inquiry groups that lasted 90 minutes 
approximately. They were run four weeks apart.
Results
Quantitative
• The mean ACEs score for service users was 2.7.
• 18% of service users reported having no ACEs in childhood.
• 58% experienced at least two ACEs.
• 33% experienced four or more ACE events in childhood.
• 40% experienced alcoholism in childhood.
• 13% experienced drug misuse.
Figure 2 identifies the most common types of ACEs by 
percentage experienced by Cuan Saor service users from 
highest to lowest.
Figure 1: The ACE pyramid
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Qualitative
Several qualitative themes emerged:
• Implementing ACEs routine enquiry:
- Training
- Implementation
• Lessons from ACEs routine enquiry:
- Relevance of the ACEs tool
- Responding to disclosures of trauma
- Timing ACEs routine enquiry within the helping process
- Understanding and empowerment of users
- Interagency work.
Implications
Several implications were put forward by the authors. 
These were based on the results of this study and the wider 
ACE literature. Four areas were identified: service users, 
practitioners, organisations, and funders.
Service users
Practitioners found that the completion of the ACEs routine 
enquiry by services users resulted in the identification of 
practice issues and responses. This information was deemed 
helpful to others implementing the ACEs routine enquiry. 
Practitioners also found that using the ACEs routine enquiry 
helped service users to come to terms with past experiences, 
leaving them in a better position to address the impact of 
the ACEs on themselves and their children. However, the 
appropriateness of the ACEs routine enquiry for older women 
was questioned.
Practitioners
ACE is one of several TIRs that has been reviewed and put into 
practice across services. However, practitioners raised some 
concerns:
• Time and resources for appropriate training and support 
around the implementation of ACEs to deal with disclosures 
that may change the service user emotionally
• The importance of boundaries and limitations when dealing 
with these issues
• The impact of dealing with ACEs on the practitioner.
Organisations
Organisations need to independently consider the best way 
to implement a TIR, the instrument to be used, training and 
support for practitioners, follow-up and referral services, and 
the evaluation process. From an interagency perspective, it 
would be important to determine whether non-governmental 
agencies and community organisations would be in a better 
position to pilot this approach in light not having the same 
constraints as larger organisations, for example, Tusla.
Funders
How to develop and fund TIRs particularly ACEs in health 
and social care was deemed to be challenging. To implement 
change, several factors need to be considered: the evidence; 
development and implementation of the intervention; 
practitioner training; getting the organisation on board; 
and resources. This study used a limited budget, existing 
supervision, and support structures within Cuan Saor and 
strong interagency relationships between IMH practitioners. 
This infrastructure may not always be available, which can 
further impact on funding.
Limitations and further research
As acknowledged by the authors, the questionnaire used in 
this study provided insight into the level and types of ACEs 
experienced by domestic violence users, thus enabling the 
implementation of a more responsive service. However, this 
approach was not intended to determine whether a causal 
link existed between ACEs in childhood and later outcomes. 
In addition, only practitioners took part in the enquiry groups. 
Also, in terms of future research, the views and impact of ACEs 
on female service users should also be assessed.
Ciara H Guiney
1 Morton S and Curran M (2019) Fostering understanding, 
empowering change: practice responses to adverse childhood 
experiences (ACEs) and intergenerational patterns of domestic 
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childhood abuse and household dysfunction to many of the 
leading causes of deaths in adults: the Adverse Childhood 
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online at:  
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Adverse childhood experiences  
continued
Reducing youth 
crime: role of 
mentoring
In October 2019, Kieran O’Dwyer, a consultant and trainer 
within the field of criminal justice and restorative practices, 
published an article, entitled Reducing youth crime: the role of 
mentoring.1 The article discussed the results of an evaluation of 
a La Chéile mentoring programme, which is delivered to young 
people aged 12–21 years who come before the criminal courts 
in Ireland.2
Mentoring programmes
Mentoring programmes are based on the idea that a 
relationship developed between a mentor (older person) and a 
mentee (younger person) may assist the young person to cope 
with adversity and may help them to cultivate a positive sense 
of themselves and their future.3 Programmes that target youths 
involved with the criminal justice system are mainly designed to 
provide support and guidance, thus enabling the young person 
to become a responsible adult. The presence of a mentor is 
also considered to offset the absence of a responsible adult in 









   












Effectiveness of mentoring in reducing 
offending
The author acknowledged that evidence on the impact of 
mentoring on reoffending is a relatively new area of research 
and lacking in clarity. For example, a report by the Ministry 
of Justice in the United Kingdom (UK) argued that analysis of 
reviews and meta-analyses was ‘promising’.5 However, the 
authors advised that results should be interpreted with caution 
due to programme variation and insufficient information on 
the mentoring context and how it was implemented.5 An earlier 
report nonetheless indicated that only some programmes 
resulted in positive outcomes.6 In contrast, a review of 
programmes supported and funded by the Youth Justice Board 
in the UK found that after one year in a mentoring programme, 
evidence to suggest offending or severity in offending had 
reduced was unconvincing.7 In fact, when reoffending rates 
were compared between mentees and corresponding national 
cohorts (n=359), rates for mentoring programmes fared worse.8
Factors critical to success in mentoring
Drawing on the research evidence base, the author identified 
several factors1 that were necessary for mentoring to be 
effective:
• Frequent contact and emotional closeness should be 
developed over a minimum period of 6–12 months.
• There should be weekly meetings of five hours or more.
• Volunteer mentors should be screened, matched, trained, 
supported and supervised.
• Attitudes and attributes of mentors should be considered.
• The advocacy role on behalf of the mentee was vital.
• The nature of the mentoring relationship should be 
considered.
• Interventions should combine mentoring and leisure-time 
programmes with a focus on psychological and sociological 
development.
• There should be an emphasis on emotional support.
• Mentoring should involve intensive training and structured 
activities.
• The organisation and administration of schemes should be 
considered.1
La Chéile mentoring
In Ireland, Le Chéile mentoring service collaborates with the 
Probation Service in Dublin, Cork, Meath, the Midlands, the 
South-East, and the South-West. Referrals are mainly made by 
the Probation Service and mentoring is carried out as part of 
probation supervision. Each area is overseen by a coordinator 
responsible for recruiting, training, supervising, and supporting 
volunteer mentors. Mentors are mainly mature persons 
(aged 20 plus) who come from all walks of life and are non-
judgemental, unbiased, and enjoy working with youth. Their 
main role is to assist, provide stability and advice, and help 
mentees make decisions and achieve goals. When a mentor and 
mentee are matched, the mentoring relationship is prioritised 
and built on via participation in social and fun activities, which 
is followed by setting attainable goals and tasks. Sessions are of 
two hours’ duration each week for approximately 6–12 months 
and occasionally longer.
Le Chéile mentoring evaluation
Methodology
Information was collected from several sources, for example, 
young people, parents, mentors, coordinators, and the 
Probation Service, via interviews and surveys. Areas examined 
via self-report included:
• Participants’ perceptions of mentoring at start and end
• Coordinators and Probation Service staff perceptions’ of 
mentees at start and end
• The extent that mentoring brought about change.
Phases of relationship building and challenging
Mentoring consisted of two phases:
1 Relationship-building phase: This lasted 6–8 weeks but 
sometimes longer and was tailored to the needs of the 
individual. The aim at this stage is for mentors and mentees 
to get to know each other and build trust via fun activities. If 
this phase is rushed, it can result in failure.
2 Challenging, target-focused phase: This prioritised goal 
setting using a ‘softly, softly’ approach, where behaviour 
and attitudes are challenged in ‘subtle, progressive, 
encouraging and supportive ways’ (p. 163).1
Results
A reduction in reoffending was reported by approximately 
28% of participants along with several other outcomes. These 
include:
• Improved family and peer relationships
• Involvement in activities outside the home
• Reduction in misuse of alcohol and drugs
• Involvement in education, work, and training
• Increased self-confidence and wellbeing (p. 10).2
In addition, several programme strengths emerged in the 
evaluation:
• Space, time, and exclusive focus on the mentee
• Patience and persistence of mentors and coordinators
• Unpaid volunteer mentors
• Personality of mentors
• Close relationships of mentees with their mentors
• Mentoring values, non-judgemental and attentive
• Provision of structure and routine
• Flexibility of mentoring
• Mentoring tailored to individual needs.
Limitations
The author acknowledged several limitations in the Le Chéile 
evaluation. No control group was utilised and the offending 
data provided was based on self-reports, not on independent 
offending data. In addition, the design of the study was not 
longitudinal. Further information on these limitations can be 
found in the evaluation report.2
Reducing youth crime   continued
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Conclusion
As acknowledged by the author, evidence from the 
international literature was mixed. Disparities between 
mentoring programmes made comparison difficult. However, 
specific aspects – such as emotional connection and 
relationship between mentor and mentee, regular contact, 
length of programme (six months or longer), structured 
activities, and parental support – have emerged as areas 
that are likely to result in positive outcomes when included. 
Evaluation of the Le Chéile mentoring programme indicated 
that offending reported by participants was negatively related 
to mentoring, that is, as mentoring increased, self-reported 
offending reduced. The author concluded that the Le Chéile 
programme provides strong evidence that mentoring results in 
participating less in criminal activities, while at the same time 
increases ‘life chances’ for those involved in the programme (p. 
165).1
Ciara H Guiney
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framework for  
Planet Youth
In February 2020, President Michael D Higgins launched the 
Planet Youth strategy and implementation framework: Galway, 
Mayo and Roscommon.1 Planet Youth was established in Ireland 
in 2018 by the Western Region Drug and Alcohol Task Force 
(WRDATF). In May 2019, the first tranche of survey data was 
published from pupils in schools across the three participating 
areas in the region (Galway, Mayo, and Roscommon).2,3,4
Planet Youth
Planet Youth is an evidence-based approach to preventing drug 
use aimed at young people. A core principle of Planet Youth is 
that prevention activities should engage the whole population 
of young people, rather than targeting particular individuals 
or groups. Developed in Iceland, the prevention model is 
predicated on three pillars of success: using evidence-based 
practice; using a community-based approach; and creating and 
maintaining a dialogue among research, policy, and practice.5 
There are three key components to the programme: data 
collection and analysis that maps out the nature of the risk 
and protective factors facing young people; implementing 
prevention activities through a wide range of stakeholders to 
increase protective factors and reduce the risk factors; and 
reflection and learning. For more detail on the background to 
the programme, see previous issues of Drugnet Ireland.6,7
Strategy framework
Planet Youth is a programme that involves a wide range of 
stakeholders from national and local government to public 
bodies, schools, and community-based organisations. The 
authors argue that ‘prevention activities are more likely to 
succeed when they are systematic, evidence-based and 
collaborative. While the need for prevention is increasingly 
recognised, it often occurs in an ad hoc manner’ (p. 19). It 
is within this context that the strategic framework has been 
developed – to encourage stakeholders to prioritise prevention 
‘in an integrated and holistic way’ (p. 19) and to support them 
in adhering to the Planet Youth model. The document outlines 
the vision, mission, guiding principles, and objectives of the 
programme in the Western Region (pp. 18–20).
Vision and mission
Vision: All young people are active, healthy and happy, 










   












Mission: To lead a process of transformative change by 
embedding primary prevention approaches which enhance 
young people’s health, relationships, environment, and 
wellbeing.
Guiding principles
1 Apply a primary prevention approach that is designed to 
enhance the social environment.
2 Emphasise community action and embrace schools as the 
natural hub of community efforts to support the wellbeing 
and development of young people.
3 Engage and empower stakeholders to make practical 
decisions using local, high-quality accessible data and 
findings.
4 Integrate researchers, policymakers, practitioners, and 
stakeholders into a unified team dedicated to solving 
complex, real-world problems.
5 Match ambition to the scale of the problem, including 
emphasising long-term actions, systems changes, and 
investment.
Objectives
1 Improve outcomes and opportunities for young people 
across the programme’s four domains: parents and family; 
leisure time and local community; school; and peer group.
2 Deliver a wide range of evidenced-informed prevention 
activities which address risk and protective factors.
Planet Youth   continued 3 At county, regional, and national level, build and maintain a strong, collaborative, well-informed partnership of 
community, agency, and political stakeholders.
4 Build strong brand recognition and stakeholder involvement 
throughout the Western Region.
5 Secure sustainable investment for development and 
coordination of Planet Youth in the Western Region.
6 Capture learning and track activities in order to inform the 
future development of Planet Youth.
7 Develop a strategy for sustaining Planet Youth linked to 
relevant national policies, including Better outcomes, 
brighter futures, the national policy framework for children 
and young people, and Reducing harm, supporting 
recovery, a health-led response to drug and alcohol use in 
Ireland, 2017–2025.8,9
Implementation framework
The authors emphasise the importance of stakeholders 
maintaining fidelity to the Planet Youth model if the best 
outcomes for young people are to be achieved. To support 
them in doing so, section 3 of the report provides guidance 
on how best to implement the model by embedding primary 
prevention approaches into their day-to-day activities. They 
identify 10 steps that aim to guide the stakeholders through 
identifying risk and protective factors within their remit 
or scope and to make changes to their policy, practice, or 
resources in order to positively impact young people’s lives. 
These steps are outlined in Figure 1.
Figure 1: Steps for implementing prevention activities
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Next steps and Covid-19
In collaboration with stakeholders, WRDATF is supporting 
the delivery of a range of prevention activities within the 
region. In line with the design of the Planet Youth programme, 
a second schools survey was due to take place in October 
2020. However, at time of print it is unclear how this will be 
implemented given the Covid-19 situation, although it is still 
hoped that it will be undertaken in some form. Covid-19 is 
recognised by Planet Youth as presenting challenges for young 
people. WRDATF is working in collaboration with the Icelandic 
Centre for Social Research and Analysis, who developed the 
programme, to include questions on the impact of Covid-19 
on young people in any future versions of the standardised 
questionnaire.
The North Dublin Regional Drug and Alcohol Task Force was 
similarly planning to implement the programme in their region, 
carrying out their initial surveys in schools in October 2020. 
This also faces delays given the Covid-19 situation.
Lucy Dillon
1 Western Region Drug and Alcohol Task Force (2020) Planet 
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2 Western Region Drug and Alcohol Task Force (WRDATF) (2019) 
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Planet Youth   continued




Cannabis continues to be the most common ‘main problem 
drug’ for new cases accessing treatment in Ireland. In 2018, it 
was reported as the main problem drug for 38% of new cases, 
followed by cocaine (31.1%) and opioids (18.1%).1 A new Irish 
study explores the experiences of a sample of teenagers (n=8) 
attending treatment for their cannabis use, entitled ‘Debt on 
me head’: a qualitative study of the experience of teenage 
cannabis users in treatment.2
Sample profile and method
The paper reports on a qualitative study based on interviews 
with eight young people in Dublin who were in treatment for 
their cannabis use. They were aged between 15 and 18 years, 
with a mean age of 16.75 years. Age at initiation of cannabis use 
ranged from 11 to 15 years, with the mean age for first use at 13 
years. On average, 3.5 years had passed since their first use. 
Interviews were recorded and transcribed verbatim. They were 
analysed thematically and six core themes were identified. Key 
findings under each theme are outlined below.
The findings of this study should be considered within the 
context of two main limitations. First, interviews were carried 
out by a member of staff from one of the treatment centres. 
This may have impacted on young people’s willingness to 
disclose certain types of information, in particular when 
discussing their views and experiences of treatment. Second, 
the sample was drawn from two Dublin-based centres and 
these young people’s experiences may therefore not reflect 
those of teenagers living in other parts of the city or the 
country.
Early initiation and heavy use
Initial cannabis use began with friends in relaxed social 
situations. However, usage became more regular and seven 
of the eight respondents progressed to daily use. This more 
regular use became less associated with feeling ‘giggly and high’ 
and more linked with ‘feeling normal’. They described feeling 
psychologically addicted and some experienced cravings and 
withdrawals when they did not use cannabis. Effects included 
sleep problems, appetite disturbance, and agitation.
Cannabis ambivalence
Respondents were found to be largely ambivalent about 
their cannabis use. On the one hand, they valued the high 
experienced and the opportunities to meet new people that 
it presented. However, on the other hand, they described in 
negative terms the costs and other effects such as anxiety 
and low mood, which they associated with heavy use. Overall, 
the negative effects were not associated with cannabis as 
such, rather with the frequency with which it was used. This 
ambivalence led to a situation whereby respondents continued 
to want to use cannabis albeit at a reduced level. ‘All but 










   













Selling cannabis, stealing money and mobile phones, and 
armed robbery were all identified as ways in which these young 
people had raised money to buy cannabis. There were also 
reports of young people getting into debt with dealers and 
threats being made to them and their families over payment of 
these debts.
Treatment
Overall, respondents were reported to have spoken favourably 
about treatment. They valued the opportunity to talk with 
well-informed, non-judgemental professionals about their 
situation. However, as noted above, these findings may have 
been impacted by the interviews having been carried out by a 
member of staff from one of the treatment centres.
Damage to relationships
In some cases, cannabis use was perceived to have caused 
problems for users in their personal relationships with friends 
and family members. There were tensions within families over 
drug debts and the associated threats, as well as some parents’ 
concerns about their young person’s drug use progressing to 
‘more harmful’ or ‘harder’ drugs.
Parental cannabis use
The final recurring theme discussed in the paper is that of 
parental cannabis use – that of either the respondent's own 
Experiences of teenagers in 
treatment for cannabis use 
continued
parents or those of their friends. While the study found that 
some of the young people knew adults who smoked cannabis, 
it was not found that parents either provided or condoned its 
use.
Conclusion
Despite the limitations of this study, Debt on me head provides 
insights into the experiences of this cohort of service users 
in an Irish context. The early onset of use and subsequent 
problems experienced, alongside their ambivalence to cannabis 
and resistance to aim for abstinence as a result of treatment, 
are shown by the authors to reflect findings elsewhere in the 
literature. Among the authors’ conclusions is that despite this 
ambivalence to the effects of cannabis ‘the financial cost of 
cannabis use and the ensuing debts appear to act as a catalyst 
to change’ (p. 217). They argue that the study emphasises ‘the 
reality that young people attending treatment for their cannabis 
use have experienced significant problems because of their 
cannabis use and cannabis dependency appears common’ (p. 
217). They highlight the need for other professionals working 
with young people to understand the negative effects that 
cannabis use may be having on these young people.
Lucy Dillon
1 Health Research Board (2019) National Drug Treatment Reporting 
System 2012–2018 drug data. Dublin: Health Research Board. 
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2 James PD, Comiskey C and Smyth BP (2019) ‘Debt on me head’: a 
qualitative study of the experience of teenage cannabis users in 
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Hepatitis C screening 
and care for opioid 
substitution patients 
in Ireland
Hepatitis C virus (HCV) is now among the most common causes 
of cirrhosis and primary liver cancer in Europe.1 As HCV is a 
blood-borne virus, people who inject drugs are the primary risk 
group for contracting HCV, making up 80% of new infections.2 
With opioid substitution increasingly being provided in primary 
care settings, they have an important role in HCV screening and 
treatment. In a 2018 study published in the Interactive Journal 
of Medical Research, Murtagh et al. investigated compliance 
in Irish primary care practices with guidelines on screening for 
HCV, other blood-borne viruses, and alcohol use disorder.3
About 74% of patients contracting HCV will become chronically 
infected, which is associated with considerable morbidity 
and mortality.4 As symptom onset can be delayed by decades 
and result in considerable damage to the liver, screening 
for HCV is vital among opioid substitution patients, who are 
often at increased risk of HCV infection due to a history of 
drug injection. Additionally, opioid substitution patients often 
present with problem alcohol use, which can exacerbate the 
risk of liver disease. Hence, guidelines from the World Health 
Organization and Health Service Executive advise on addressing 
alcohol use with HCV patients.
Effective diagnostic technology (e.g. FibroScan) and treatment 
for HCV (direct-acting antiviral (DAA) treatment) are now 
available, but due to the high cost of treatment, guidelines 
prescribe prioritising patients with the highest clinical need.5 
Additionally, scarce time and resources can complicate 
treatment within primary care. Given new options and plans to 
expand HCV interventions, the study’s aim was to investigate 
whether opioid substitution patients were receiving HCV 
screening and care in line with best practice guidelines.
Methods
The study used baseline data from the larger HepLink study on 
developing community-based HCV treatment interventions. 
Participants were opioid substitution patients recruited through 
non-probability sampling, which was deemed an acceptable 
method for the HepLink feasibility study. Of 63 general 
practices in the selected study area (Mater Misericordiae 
University Hospital catchment area in Dublin), 14 practices 
participated, each recruiting 10 participants. In total, 134 
patients participated, 71.6% of whom were male. Their mean 
age was 43 years. Data were collected from patient records and 
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included information on screening, treatment, and vaccination 
for blood-borne viruses (HCV, hepatitis B virus (HBV), and HIV), 
and drug and alcohol use.6
Key findings
HCV
• HCV screening: In their lifetime, 94.8% of participants had 
been screened for HCV (23.9% in the past year); 77.9% of 
whom tested positive for HCV at least once (72% of patients 
tested in the past year; see Figure 1).
• Interventions: Only 17% of HCV-positive participants 
had had a FibroScan and only 20% had started HCV DAA 
treatment (3% in the past year; see Figure 2).
HIV and HBV
• HIV screening: 83.6% of participants had been screened 
for HIV in their lifetime (25.4% in the past year), 6.3% of 
whom tested positive (3% of patients tested in the past 
year).
• HBV screening: 66.4% of participants had been screened 
for HBV in their lifetime (22.4% in the past year), 8% of 
whom tested positive (3% of patients tested in the past 
year).
• Vaccination: 48.5% of patients had previously been 
vaccinated against HBV (8% in the past year).
Drug and alcohol use
• Alcohol screening: Clinical records showed that 30.6% of 
participating patients had been asked about their alcohol 
consumption by their general practitioners (GPs) in the past 
year.
• Interventions: Only 6% had received a brief intervention 
and 2.2% had a referral to specialist addiction services.
• Drug screening: 37.3% of participants’ last urine sample 
showed metabolites of non-prescribed drugs.
Discussion
Murtagh et al. welcome the high rate of HCV screening of 
94.8% in this study, noting that this is a considerable increase 
from 69% in a 2003 study.7 In contrast, the low proportion of 
HCV-positive participants receiving treatment is concerning. 
The authors attribute this to the high cost of DAA treatment, 
necessitating the triaging of patients. They envisage that as 
antiviral medication becomes cheaper, its availability will 
increase for Irish HCV patients.
Less than one-third of patients had been screened for problem 
alcohol use, and brief interventions and referrals were only 
scarcely provided. While this represents an improvement from 
previous studies,8,9 the authors note that this is still insufficient 
given the risks to liver health of both HCV and alcohol use. Also 
considering the high proportion of opioid substitution patients 
with substance use in the study, Murtagh et al. conclude that 
GPs should be trained to provide more brief interventions and 
harm reduction education for their opioid substitution patients.

























Figure 1: Percentage of participants ever screened for HCV (n=134) and results for those screened (n=127)

































   












Compared with previous findings in Ireland, the rates of 
patients in this study testing positive for HCV (77.9%) and for 
HBV (8%) are higher, whereas the rates for HIV (6.3%) are lower 
or similar.7,8 However, these differences should be interpreted 
with caution due to the variation in sample sizes and source of 
comparison data.
The study’s findings must be viewed in light of further 
limitations, including limited generalisability due to the non-
randomised sampling technique and potential self-selection 
bias among participating GPs. Murtagh et al. also note the 
imperfections of clinical records as a data source on viral 
screening, as they do not capture care provided to patients in 
other practices. Nevertheless, the study provides important 
insights into the status quo of screening and care for informing 
the expansion of HCV treatment.
Britta Thiemt
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The Danger of Viral Exposure (DOVE) Service in the Rotunda 
Hospital, Dublin was established to meet the specific needs of 
pregnant women who have, or are at risk of, blood-borne or 
sexually transmitted bacterial or viral infections in pregnancy. 
Exposure may also occur through illicit drug use. Figures from 
the service for 2018 were published in the hospital’s annual 
report in 2019.1
Figure 1 shows the number of women who booked into the 
DOVE Service for antenatal care each year during the period 
2008–2018. It also shows the diagnosis for these women.
During 2018, some 128 women booked into the DOVE Service 
for antenatal care. Of these:
• 31 (24%) women were positive for HIV infection.
• 41 (32%) women were positive for hepatitis B (HBV) surface 
antigen.
• 41 (32%) women were positive for hepatitis C (HCV) 
antibody.
• 20 (16%) women had positive treponemal serology (syphilis).
In addition to the figures presented above, a number of 
women attended the service for diagnosis and treatment of 
human papillomavirus, herpes simplex virus, chlamydia, and 
gonorrhoea.
It should be noted that these numbers refer to patients who 
booked for care during 2018. Table 1 summarises the outcome 
of patients who actually delivered during 2018. Of these 
patients, 30 were HIV-positive, 48 were HBV-positive, and 
42 were HCV-positive. During 2018, some 106 women were 
referred to the Drug Liaison Midwife (DLM) service, including 
39 women who had a history of opiate addiction and were 
engaged in a Methadone Maintenance Programme. There was a 
total of 61 deliveries to mothers under the DLM service in 2018.
27
Issue 74  |  Sum
m
er 2020     drugnet IRELAND      
DOVE report, 2018   continued
Seán Millar
1 The Rotunda Hospital (2019) The Rotunda Hospital Dublin annual 


















2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
37 55 36 27 36 24 25 24 27 26 31
76 59 76 85 70 59 43 64 58 49 41
74 63 63 74 61 59 51 55 40 36 41





Figure 1: DOVE Service bookings by year, 2008–2018
Source: The Rotunda Hospital (2019)







Total mothers delivered 30 48 42 16 61
Total mothers delivered <500 g (incl. miscarriage) 0 0 1 0 0
Total mothers delivered >500 g 30 48 41 16 61
Live infants 31* 48 43*** 16 63***
Miscarriage 0 0 1 0 0
Stillbirth 0 0 0 0 0
Infants <37 weeks’ gestation 8 1 10 1 7
Infants ≥37 weeks’ gestation 23 47 33 15 56
Caesarean section 15 17 15 5 15
HIV, HBV, HCV or syphilis-positive infants 0 0** 0** 0 -
Maternal median age 34 31 32 34 -
Table 1: Deliveries to mothers attending the DOVE Service who were positive for HIV, HBV, HCV or syphilis, or who were attending  
the drug liaison midwife, 2018
Source: The Rotunda Hospital (2019)
* One set of twins.
** Final serology test not yet available for all infants.
*** Two sets of twins.









   











0 Trends in alcohol and 
drug admissions to 
psychiatric facilities
The annual report published by the Mental Health Information 
Systems Unit of the Health Research Board, Activities of Irish 
psychiatric units and hospitals 2018,1 shows that the rate of 
new admissions to inpatient care for alcohol disorders has 
decreased.
In 2018, some 1,086 cases were admitted to psychiatric facilities 
with an alcohol disorder, of which 389 were treated for the first 
time. Figure 1 presents the rates of first admission between 1998 
and 2018 for cases with a diagnosis of an alcohol disorder. The 
admission rate in 2018 was lower than the previous year, and 
trends over time indicate an overall decline in first admissions. 
One-third of cases hospitalised for an alcohol disorder in 
2018 stayed just under one week, while 33% of cases were 
hospitalised for between one and three months, similar to 
previous years.
In 2018, some 995 cases were admitted to psychiatric facilities 
with a drug disorder. Of these cases, 408 were treated for the 
first time. Figure 2 presents the rates of first admission between 
1998 and 2018 of cases with a diagnosis of a drug disorder. 
Although the rate decreased slightly in 2018, there has been 
an overall increase in the rate of first admission with a drug 
disorder since 2011. It should be noted that the report does 
not present data on drug use and psychiatric comorbidity; 


























1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
43.8 41.7 41.0 39.9 36.1 30.5 24.3 24.5 20.1 19.1 18.6 16.0 15.0 12.9 11.4 12.5 10.4 9.5 9.7 9.2 8.2Rates
Figure 1: Rates of psychiatric first admission of cases with a diagnosis of an alcohol disorder per 100,000 of population in Ireland, 1998-2018





















1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
7.2 7.9 7.8 8.4 6.3 6.1 6.7 7.9 5.9 6.3 6.8 7.4 9.7 7.7 7.8 8.0 8.9 9.8 9.0 8.7 8.6Rates
Figure 2: Rates of psychiatric first admission of cases with a diagnosis of a drug disorder per 100,000 of population in Ireland, 1998-2018
Source: Daly and Craig (2019)
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Other notable statistics on admissions for a drug disorder in 
2018 include the following:
• Less than one-half of cases hospitalised for a drug disorder 
stayed under one week (48%), while 99% were discharged 
within three months. It should be noted that admissions and 
discharges represent episodes or events and not persons.
Admissions to psychiatric 
facilities 
continued
• 17% of first-time admissions were involuntary.
• Similar to previous years, the rate of first-time admissions 
was higher for men (13.8 per 100,000 population) than for 
women (3.5 per 100,000 population).
Seán Millar
1 Daly A and Craig S (2019) Activities of Irish psychiatric units and 





The 17th annual report from National Self-Harm Registry Ireland 
was published in 2019.1 The report contains information relating 
to every recorded presentation of deliberate self-harm to 
acute hospital emergency departments in Ireland in 2018 and 
complete national coverage of cases treated. All individuals 
who were alive on admission to hospital following deliberate 
self-harm were included, along with the methods of deliberate 
self-harm that were used. Accidental overdoses of medication, 
street drugs, or alcohol were not included.
Rates of self-harm
There were 12,588 recorded presentations of deliberate self-
harm in 2018, involving 9,785 individuals. Taking the population 
into account, the age-standardised rate of individuals 
presenting to hospital in the Republic of Ireland following self-
harm was 210 per 100,000 population. This was a significant 
increase of 6% compared with the rate recorded in 2017 (199 
per 100,000 population). The rate in 2018 was 12% higher than 
in 2007, the year before the economic recession (see Figure 1).
In 2018, the national male rate of self-harm was 193 per 100,000 
population, 7% higher than in 2017. The female rate was 229 
per 100,000 population, which was 5% higher than in 2017. 
With regard to age, the peak rate for men was in the 20–24-age 
group, at 543 per 100,000 population. The peak rate for women 
was among 15–19-year-olds, at 766 per 100,000 population.
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
167 177 170 167 160 162 180 197 211 205 195 182 185 186 184 181 193

























Figure 1: Person-based rate of deliberate self-harm from 2002 to 2018 by gender
Source: National Suicide Research Foundation (2019)









   












Self-harm and drug and alcohol use
Intentional drug overdose was the most common form of 
deliberate self-harm reported in 2018, occurring in 7,792 
(61.9%) of episodes. As observed in 2017, overdose rates were 
higher among women (66.9%) than among men (55.8%). Minor 
tranquillisers and major tranquilisers were involved in 35% and 
10% of drug overdose acts, respectively. In total, 34% of male 
and 48% of female overdose cases involved analgesic drugs, 
most commonly paracetamol, which was involved in 30% of 
all drug overdose acts. In 69% of cases, the total number of 
tablets taken was known, with an average of 29 tablets taken in 
episodes of self-harm that involved a drug overdose.
In 2018, there was an increase in the number of self-harm 
presentations to hospital involving street drugs by 27% (from 
583 to 742). Since 2007, the rate per 100,000 of intentional drug 
overdose involving street drugs has increased by 54% (from 9.9 
to 15.3 per 100,000 population). Cocaine and cannabis were the 
most common street drugs recorded by the registry in 2018, 
present in 5% and 3% of overdose acts, respectively. Cocaine 
was most common among men, involved in 15% of overdose 
National Self-Harm Registry 
annual report, 2018 
continued
acts by 25–34-year-olds. Cannabis was most common among 
men aged 5–24 years old, and was present in 8% of overdose 
acts. Alcohol was involved in 30% of all self-harm presentations 
in 2018, and was significantly more often involved in male 
episodes of self-harm than females (34% vs 27%, respectively).
Street drugs and self-harm
The sharp increase in the use of street drugs involved in 
self-harm presentations in 2018 – in particular cannabis – was 
discussed. A recent systematic review and meta-analysis found 
that cannabis consumption in adolescence was associated 
with increased risk of developing major depression in young 
adulthood, and an increased risk of suicidal ideation and 
suicide attempts in young adulthood.2 The report authors 
suggest that public health policies to address the use of illegal 
substances should be further developed.
Seán Millar
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opioid substitution  
in hospital setting 
In December 2016, the Health Service Executive (HSE) launched 
its clinical guidelines for opioid substitution treatment (OST)1 
in conjunction with the College of Psychiatrists of Ireland, the 
Irish College of General Practitioners, and the Pharmaceutical 
Society of Ireland. Appropriate policies and standard operating 
procedures for the delivery of inpatient OST are essential 
for patient safety when treating a person with an opioid 
dependency.
Following the publication of those guidelines, it became 
apparent that there was a need for a specific set of guidelines 
covering inpatient aspects for the prescribing and dispensing of 
OST within the hospital setting.2 
Having identified the specific need for guidance within the 
hospital setting, the new document is an adjunct to Clinical 
guidelines for opioid substitution treatment. It is divided 
into seven sections, each covering the different aspects 
of OST treatment: the guiding principles; rehabilitation 
and psychosocial components of OST; principles and key 
operational stages of pharmacological interventions of OST; 
assessment of dependence and management of OST; drug 
testing; OST and associated health considerations; and specific 
treatment situations and populations.3,4
A brief summary of the key points specific to the hospital 
setting is provided below.
OST in hospital setting
• The main objective of drug treatment in hospital is to 
stabilise drug misuse as quickly as possible in order to treat 
a drug-related or non-drug-related condition.
• Occasionally, patients may use the opportunity afforded 
by a hospital admission to reduce their drug use or to 
complete a detoxification. This may be useful, but if 
unplanned, it is likely to result in relapse upon leaving 
hospital, in turn exposing the patient to a higher risk of 
overdose.
• Transfer of care upon both admission and discharge require 
a coordinated response by treating staff.
• Routine planned admissions to hospital are preferable.
• Acute hospital settings and mental health inpatient units 
should have access to naloxone in case of opioid overdose.
• Substitute opioids or other controlled drugs should only be 
prescribed following a comprehensive assessment. 
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Assessment aims
1  Facilitate treatment of an emergency or acute problem or 
for an elective procedure to take place
2 Confirm the patient is taking drugs (history, examination, 
urinalysis)
3  Identify any complications of drug misuse and evaluate risk 
behaviours (blood-borne viral screening, nutrition, alcohol 
intake)
4  Consider psychiatric comorbidity.
Patients currently being prescribed  
methadone or buprenorphine
Prescribing should be a straightforward continuation of the 
patient’s usual dose of OST while in hospital. Communication 
between the hospital and community is vital for safe patient 
care. The Central Treatment List (CTL) should be contacted to 
confirm that the patient is receiving OST. The CTL is available 
9am–5pm, Monday to Friday, at 01 648 8638.
• Confirmation of the dose by the patient alone is not 
adequate. 
• Confirmation of the last dose received at the clinic should 
be sought by contacting the clinic or dispensing pharmacy 
directly.
Patients not receiving OST
Where there is uncertainty about recent compliance, care must 
be exercised when initiating OST. Local drug treatment services 
should be contacted upon initiation to ensure continuity of 
care upon discharge. 
Initial dosing schedule for opioid-dependent 
patients admitted to hospital
• OST should only be prescribed following an assessment.
• Polydrug and alcohol misusers may develop multiple 
withdrawal syndromes, so these may need to be discerned 
in order to prioritise treatment.
• Methadone may initially mask alcohol or benzodiazepine 
withdrawal symptoms.
• Care should be exercised when prescribing additional 
drugs, such as sedatives, to individuals who may also be 
using illicit substances. Interactions between street drugs 
and psychotropic drugs should always be considered. 
• Clinicians should refer to a relevant text, such as Maudsley 
Prescribing Guidelines (2018).5
• Where it is appropriate to initiate opioid substitution 
in hospital to reduce risk of withdrawal, methadone or 
buprenorphine can be used.
• OST induction should always follow the methadone 
treatment protocol (MTP). However, close supervision in 
hospital may allow for a modified protocol.  
• Signs of intoxication, such as drowsiness, slurred speech, 
or pupil constriction, indicate the need to discontinue or 
reduce the dose of the drug.
• Hospitals should contact the CTL before prescribing 
buprenorphine products to ensure continuity 
post-discharge, as HSE approval is required before 
buprenorphine products can be reimbursed in the 
community setting. 
Other drugs of misuse
Opioid-dependent patients in hospital may be taking other 
drugs and misusing alcohol.
• Misuse of benzodiazepines or alcohol could lead to 
associated withdrawal symptoms and seizures.
• Benzodiazepine prescribing should only be initiated once 
the level of dependence has been established through 
history taking and noting any symptoms of withdrawal. 
Within the inpatient setting, it is appropriate to provide a 
withdrawal regimen over one to four weeks, with a starting 
dose of diazepam no more than 30 mg daily, administered in 
divided doses. 
 
• For useful tools and schedules, see the 2016 community 
detoxification guidelines issued by Ana Liffey Drug Project.6
• Routine prescribing of benzodiazepines, Z-drugs, or 
gabapentinoids should be avoided while in hospital, 
especially the use of pregabalin as an anxiolytic.
• Patients may also need a simultaneous detoxification from 
alcohol. 
Pain management
Management of patients if nil by mouth (NPO).7
• Specialist advice should be sought from the anaesthetist 
for perioperative and NPO instructions.
• Postoperatively methadone should be restarted once the 
NPO instruction has been removed.
• Should the NPO instruction remain postoperatively, both 
potential opioid withdrawal and pain should be managed 
using a conventional opioid, such as morphine injection/
infusion. Intravenous methadone should not be used 
instead of the oral methadone due to differences in dose 
equivalence by route of administration.
• If monitoring indicates the patient may be in opioid 
withdrawal or pain, referral to a specialist pain team may be 
required. 
Discharge from hospital
For drug misusers not previously in treatment, attendance at 
the emergency department or hospital admission may present 
a window of opportunity to put them in touch with other 
services. It is essential to link with services well in advance 
of discharge to ensure continuity of care. This is in line with 
the HSE Code of Practice for Hospital Integrated Discharge 
Planning.
On discharge, the following information should be given:
• General health promotion advice
• Contact details for further help, such as needle exchange, 
drug treatment services, or self-help groups. (Refer to the 
directory of services for your area on www.drugs.ie) 
• Advice on overdose prevention 
• Advice on reducing the risk of blood-borne viruses and 
hepatitis B vaccination 
• Advice on loss of tolerance in hospital.









   












Where a patient is receiving an opioid prescription upon 
admission from the community, this should be continued on 
discharge with prescribing responsibility transferring back to 
the GP or HSE addiction clinic. Discharge planning is best done 
in collaboration with local drug treatment services, the GP, and 
the community pharmacy. 
On the day of discharge, confirm the following with the 
community services:
• Patients should receive their substitution dose on the day 
of discharge; their clinic or GP and community pharmacy 
should be contacted to confirm they have received that 
day’s dose.
• Details of other drugs prescribed while an inpatient should 
be provided.
• Prior to discharge, confirmation should be provided that 
the patient is registered with a methadone-prescribing GP 
and a community pharmacy for continuation of OST.
OST guidelines   continued Suzi Lyons
1 Health Service Executive (2016) Clinical guidelines for opioid 
substitution treatment. Dublin: Health Service Executive.  
https://www.drugsandalcohol.ie/26573/
2 Health Service Executive (2020) Clinical guidelines for opioid 
substitution treatment: guidance document for OST in the hospital 
setting Dublin: Health Service Executive.  
https://www.drugsandalcohol.ie/31766/
3 Note that the prescription of OST in hospital settings is covered 
under the Misuse of Drugs (Supervision of Prescription and Supply 
of Methadone and Medicinal Products containing Buprenorphine 
authorised for Opioid Substitution Treatment) Regulations 2017. 
The regulations add certain buprenorphine medicinal products 
authorised for OST to the schedule of products that fall within the 
scope of these regulations. These regulations replace the Misuse 
of Drugs (Supervision of Prescription and Supply of Methadone) 
Regulations 1998 (SI No. 225 of 1998).
4 Lyons S (2017) New clinical guidelines for opioid substitution 
treatment. Drugnet Ireland, 62: 27–30.  
https://www.drugsandalcohol.ie/27752/
5 Taylor DM, Barnes TRE and Young AH (2018) The Maudsley 
prescribing guidelines in psychiatry, 13th edn. Chichester: Wiley 
Blackwell.
6 Ana Liffey Drug Project (2016) National community detoxification: 
methadone guidelines. Dublin: Ana Liffey Drug Project.  
https://www.drugsandalcohol.ie/26888/ 
7 British Pain Society (2007) Pain and substance misuse: improving 
the patient experience. A consensus statement prepared by the 
British Pain Society in collaboration with the Royal College of 
Psychiatrists, the Royal College of General Practitioners and the 
Advisory Council on the Misuse of Drugs. London: British Pain 
Society. https://www.drugsandalcohol.ie/6343/ 
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Recent publications
PREVALENCE AND CURRENT SITUATION
Competing priorities and second chances – a qualitative 
exploration of prisoners' journeys through the hepatitis C 
continuum of care
Crowley D, Cullen W, Lambert JS and Van Hout MC (2019) PLoS 
ONE, 14(9): e0222186. 
https://www.drugsandalcohol.ie/31836/ 
This study aimed to explore Irish prisoners' experience of prison 
and community-based HCV [hepatitis C virus] care. We conducted 
one-to-one interviews with 25 male prisoners with chronic HCV 
infection. Data collection and analysis was informed by grounded 
theory.
The study generated a substantive theory of the need to increase 
the importance of HCV care among the routine competing 
priorities associated with the lives of PWID [people who inject 
drugs]. HCV infected prisoners often lead complex lives and 
understanding their journeys through the HCV continuum can 
inform the development of meaningful HCV care pathways. Many 
challenges exist to optimising HCV treatment uptake in this group 
and incarceration is an opportunity to successfully engage HCV 
infected prisoners who underutilise and are underserved by 
community-based medical services. Support and linkage to care 
on release is essential to optimising HCV management.
Assessing the European impact of alcohol misuse and illicit 
drug dependence research: clinical practice guidelines and 
evidence-base policy
Pallari E, Soukup T, Kyriacou A and Lewison G (2020)  
Evidence-Based Mental Health, 23(2): 67–76. 
https://www.drugsandalcohol.ie/31815/ 
This study sought to (1) evaluate European research outputs on 
alcohol misuse and drug addiction in 2002–2018 in the Web of 
Science, (2) compare these with their burden of disease and (3) 
determine their impact in several ways.
The volume of research on illicit drug addiction is commensurate 
to the European burden, whereas alcohol misuse is far below what 
is needed to curb a significant source of harm.
The research asymmetries call for attention to the causes of 
the problem. Development of research-based solutions to a 
serious social harm is needed, including minimum pricing and 
collaborative work to harmonise efforts on disease management 
and treatment practices across European countries.
National Drugs Library
Trends in the use of mind-altering drugs among European 
adolescents during the Great Recession
Balbo N, Carpella P and Toffolutti V (2020) Health Policy, 124(5): 
568–574. 
https://www.drugsandalcohol.ie/31775/ 
This study uses data on adolescents between 15 and 17 years old 
from 25 European countries to test, if and how, the substance-use 
pattern has changed during the Great Recession. 
Social protection expenditure reduces the use of inhalants, 
whereas ecstasy consumption rises. The pattern for cocaine is 
unclear.
Memory and attention during an alcohol hangover
Devenney LE, Coyle KB and Verster JC (2019) Human 
Psychopharmacology, 34(4): e2701. 
https://www.drugsandalcohol.ie/31736/ 
This study aims to investigate attention, memory functioning, and 
mood in a natural setting with real-life alcohol consumption levels.
Selective attention was significantly impaired during alcohol 
hangover. The differences between the hangover and control 
group did not reach significance for other forms of attention or 
memory.
Media coverage of major sporting events: alcohol, crowd shots 
and the Rugby World Cup 2019
Houghton F and McInerney D (2020) Irish Journal of Medical 
Science, Early online. 
https://www.drugsandalcohol.ie/31703/ 
This examination focuses on Raidió Teilifís Éireann (RTÉ) coverage 
of the recent Rugby World Cup match between Ireland and New 









   












Factors associated with requests for premature discharge and 
the decision to support a service user through the discharge 
against medical advice process
Kavanagh A, Donnelly J, Dunne N, Maher T, Nichol M and Creedon 
J (2020) International Journal of Mental Health Nursing, 29(4): 
716–724. 
https://www.drugsandalcohol.ie/31702/ 
This study is a retrospective review of clinical records to identify 
factors associated with requests for premature discharge. 
Considerations of clinicians making the decision to detain the 
person or to support them through the discharge against medical 
advice process were also elucidated. Data were collected from 
clinical records of service users who requested discharge and 
were subsequently discharged against medical advice or detained 
involuntarily.
Discharge against medical advice represented 3.5% of all 
discharges. The most frequent reasons for requests for discharge 
against medical advice were dissatisfaction with treatment, lack of 
engagement due to addiction, and leaving without notifying staff. 
Requests for discharge against medical advice frequently occurred 
out of hours, and nurses were the clinicians most likely to receive 
such requests.
Adding more 'spice' to the pot: a review of the chemistry 
and pharmacology of newly emerging heterocyclic synthetic 
cannabinoid receptor agonists
Alam RM and Keating JJ (2020) Drug Testing and Analysis, 12(3): 
297–315. 
https://www.drugsandalcohol.ie/31691/ 
At present, little information is available regarding the chemical 
syntheses of the newly emerging classes of synthetic cannabinoid 
receptor agonists (SCRAs), from a clandestine perspective.
When compared with previous generations of indole- and 
indazole-type SCRAs, current research suggests that many 
of these heterocyclic SCRA analogs maintain high affinity and 
efficacy at both CB1 and CB2 (cannabinoid receptor type 1 and 
2) but largely evade legislative control. This review highlights the 
importance of continued research in the field of SCRA chemistry 
and pharmacology, as recreational SCRA use remains a global 
public health issue and represents a serious control challenge for 
law enforcement agencies.
A descriptive survey of online gaming characteristics and 
gaming disorder in Ireland
Columb D, Griffiths MD and O’Gara C (2020) Irish Journal of 
Psychological Medicine, Early online, pp. 1–9. 
https://www.drugsandalcohol.ie/31665/ 
The aim of this study was to carry out the first ever study of 
gaming characteristics of individuals engaging in online gaming in 
Ireland and to ascertain whether features of gaming disorder are 
present in this population.
A small percentage of gamers in Ireland demonstrate disordered 
gaming characteristics and gaming disorder, consistent with data 
from other international studies. Epidemiological studies are 
required in Ireland to enhance our knowledge of this disorder.
High-cost, high-need users of acute unscheduled HIV care: a 
cross-sectional study
Grant C, Bergin C, O’Connell S, Cotter J and Ní Cheallaigh C (2020) 
Open Forum Infectious Diseases, 7(2): ofaa037. 
https://www.drugsandalcohol.ie/31664/ 
High-cost, high-need users are defined as patients who 
accumulate large numbers of emergency department visits 
and hospital admissions that might have been prevented by 
relatively inexpensive early interventions and primary care. This 
phenomenon has not been previously described in HIV-infected 
individuals.
A small number of HIV-infected individuals account for a high 
volume of acute unscheduled care. Intensive engagement in 
outpatient care may prevent some of this usage and ensuing costs.
Journeying with fear: young people's experiences of cannabis 
use, crime and violence before treatment entry
Comiskey C, James P and Smyth B (2020) Journal of Child and 
Adolescent Psychiatric Nursing, 33(2): 61–66. 
https://www.drugsandalcohol.ie/31639/
The experiences of crime and policing from the perspective of 
adolescent cannabis users before treatment entry are not often 
understood by practitioners.
Findings of this study highlight the commonality of fear and the 
seriousness of personal and familial violent harms. The need for 
targeted developmental preventions in vulnerable settings is 
proposed. Parents and professionals need to have an awareness 
of money in the home and the role of intergenerational substance 
use.
Do interruptions to the continuity of methadone maintenance 
treatment in specialist addiction settings increase the risk of 
drug-related poisoning deaths? A retrospective cohort study
Durand L, O’Driscoll D, Boland F, Keenan E, Ryan B, Barry J, et al. 
(2020) Addiction, Early online. 
https://www.drugsandalcohol.ie/31615/
This study aimed to examine the risk of mortality associated 
with interruptions to the continuity of methadone maintenance 
treatment (MMT), including transfers between services, in  
opioid-dependent individuals attending specialist addiction 
services.
Interruptions to the continuity of methadone maintenance 
treatment by treatment provider do not appear to be periods of 
risk for drug related poisoning or all-cause mortality deaths. Risk 
of drug related poisoning and all-cause mortality deaths appears 
to be greatest during the first four weeks of treatment initiation/
re-initiation and after treatment cessation.
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Risk and protective factors for psychotic experiences in 
adolescence: a population-based study
McMahon EM, Corcoran P, Keeley H, et al. (2020) Psychological 
Medicine, Early online, pp. 1–9. 
https://www.drugsandalcohol.ie/31608/
The aims of this study were to examine associations between 
psychotic experiences (PEs) and a range of factors including 
psychopathology, adversity and lifestyle, and to investigate 
mediating effects of coping style and parental support on 
associations between adversity and PEs in a general population 
adolescent sample.
We have identified potential risk factors for PEs from 
multiple domains including adversity, mental health and 
lifestyle factors. The mediating effect of parental support on 
associations between adversity and PEs suggests that poor 
family relationships may account for some of this mechanism. 
These findings can inform the development of interventions for 
adolescents at risk.
Association between electronic cigarette use and smoking 
cessation in the European Union in 2017: analysis of a 
representative sample of 13 057 Europeans from 28 countries
Farsalinos KE and Barbouni A (2020) Tobacco Control, Early 
online. 
https://www.drugsandalcohol.ie/31605/ 
This study aimed to examine the association between 
electronic cigarette (e-cigarette) use and smoking cessation in 
the European Union (EU) in 2017 according to e-cigarette use 
frequency and smoking cessation duration.
Current daily e-cigarette use in the EU in 2017 was rare among 
former smokers of >10 years and was positively associated with 
recent (≤5 years) smoking cessation. Former daily e-cigarette 
use was also positively associated with recent (≤2 years) 
smoking cessation.
POLICY
AIDS inside and out: HIV/AIDS and penal policy in Ireland and 
England & Wales in the 1980s and 1990s
Weston J and Berridge V (2020) Social History of Medicine, 33(1): 
247–267. 
https://www.drugsandalcohol.ie/31606/ 
This article compares the policy decisions made by the prison 
services of the Republic of Ireland and England & Wales in 
response to HIV/AIDS in the 1980s and 1990s, bringing together 
the histories of penal policy and HIV/AIDS for the first time. It 
develops our understanding of contemporary policy history, 
and demonstrates the value of a comparative approach to 
both penal and health histories. Policy-making was shaped by 
both national and more localised traditions and trends, from 
attitudes to criminal justice and responses to HIV/AIDS at the 
national level, to the histories, structures, and staffing of prison 
services themselves.
Enhancing implementation of smoke-free places: a 
comparative qualitative study across seven European cities
Mlinarić M, Hoffmann L, Lindfors P and Richter M (2020) Social 
Science & Medicine, 247: 112805. 
https://www.drugsandalcohol.ie/31599/ 
The aim of this qualitative comparative study is to identify and 
classify the smoke-free (SF) policy implementation processes 
and types undertaken at the local level in seven European cities 
according to the views of local bureaucrats and sub-national 
stakeholders.
This study found four SF implementation types two mechanisms 
of progressive expansion and defensive closure. Development 
and enhancement of smoking bans requires a suitable national 
policy environment and indirect national-level support of self-
governed local initiatives. Future SF policies can be enhanced 
by laws pertaining to places frequented by minors.
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Methadone, Pierre Robin sequence and other congenital 
anomalies: case–control study
Cleary B, Loane M, Addor M-C, et al. (2020) Archives of Disease 
in Childhood (Fetal and Neonatal edn), 105(2): 151–157. 
https://www.drugsandalcohol.ie/31690/ 
Methadone is a vital treatment for women with opioid use 
disorder in pregnancy. Previous reports suggested an association 
between methadone exposure and Pierre Robin sequence 
(PRS), a rare craniofacial anomaly. We assessed the association 
between gestational methadone exposure and PRS.
The findings suggest that gestational methadone exposure 
is associated with PRS. The association may be explained by 
unmeasured confounding factors. The small increased risk 
of PRS in itself does not alter the risk-benefit balance for 
gestational methadone use. The association with cleft palate, a 
more common CA [congenital anomalies], should be assessed 
with independent data.
Electronic cigarettes and obstetric outcomes: a prospective 
observational study
McDonnell BP, Dicker P and Regan CL (2020) BJOG, 127(6): 
750–756. 
https://www.drugsandalcohol.ie/31784/ 
This study aimed to compare the obstetric outcomes and 
socio-demographic factors in electronic cigarette (EC) users 
with cigarette smokers and non-smokers in pregnancy.
The birthweight of infants born to EC users is similar to that of 
non-smokers, and significantly greater than cigarette smokers. 
Dual users of both cigarettes and EC have a birthweight similar 
to that of smokers.
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